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Smith Magenis Syndrome (SMS, OMIM#182290) is a sporadic dominant disorder, with an estimated 
prevalence of 1:15000-25000 and results from RAI1 gene haploinsufficiency due to either 17p11.2 
deletion or RAI1 mutation. SMS has a clinically recognizable phenotype characterized by distinct physical 
features, neurodevelopmental delay, cognitive impairment and behavioral problems which are reported 
in 75-100% of SMS cases, and include remarkable sleep disturbance (primarily due to circadian rhythms 
impairment), stereotypies, maladaptive, self-injurious behavior and sensory processing issues. SMS 
diagnosis is challenging due to the lack of a striking early childhood facial phenotype, maladaptive 
behavior that escalates with age, and overlapping syndromes that share with SMS most of the clinical 
signs and might switch to a differential diagnosis, i.e. 2q23.1 deletion syndrome (OMIM#156200) and 
Brachydactly Mental Retardation syndrome (BDMR, OMIM#600430).  
Despite RAI1 is recognized as the disease-causing gene, 50% of patients with a clinical suspicion of SMS 
do not have the classical genetic defects, thus it is likely that at genomic level other loci different from 
RAI1, if disrupted, eventually explain SMS similar phenotypes (SMS-like). Hence, even if several animal 
models support RAI1 crucial contribution to brain development and plasticity, by interacting at 
chromatin promoter and enhancer regions, compelling evidences on its function, regulators, interactors, 
and targets are still missing.  
In order to unveil the molecular basis of SMS-like syndrome and to clarify RAI1 molecular function, the 
main aim of this project will be a genetic and functional investigation of RAI1 and candidate genes 
possibly implicated in SMS-like clinical manifestation.  
A previously selected cohort of 40 SMS-like patients with a clinical suspicion of SMS but without the 
classical microdeletion at 17p11.2 or RAI1 mutation was available in Medical Cytogenetics and 
Molecular Genetics Laboratory. High resolution array CGH screening of whole cohort was used to 
identify Copy Number Variants (CNVs) potentially containing dosage-sensitive genes eventually involved 
in neurological integrity maintenance, cognition and development, thus putatively implicated in SMS 
and “SMS-like” clinical condition. Among 40 SMS-like patients cohort the whole genome analysis 
pinpointed the attention on a CNV, specifically a 54 kb maternal deletion on Xq13.3 (chrX:74772380-
74826319, hg19) in one male patient (SMS1). The Xq13.3 deletion does not involve any gene but 
contains highly conserved region, a predicted insulator and maps 29 kb far from 5’ end of the ZDHHC15 
(Zinc Finger DHHC domain-containing protein 15) gene which encodes for palmitoyl-transferase 15 
ubiquitously expressed, but highly expressed in the brain. ZDHHC15 was considered an interesting gene 
possibly implicated in patient phenotype onset due to its function and because was previously 
associated to a nonsyndromic X-linked intellectual disability. RT-qPCR and digital PCR analyses 
performed on SMS1 cDNA from peripheral blood revealed a significant downregulation of the ZDHHC15 
transcript, supporting  that the CNV involving a predicted insulator element results in gene expression 
alteration by a position effect. Consistent with a possible involvement of ZDHHC15 in SMS-like 
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phenotypes, subsequent Sanger sequencing of all male patients within the cohort was performed and 
identified a maternally inherited transversion, c.*182A>C, on ZDHHC15 3’UTR in a second male patient 
(SMS2). In order to clarify any transcriptional effect on ZDHHC15 regulation caused by transversion, 
both relative RT-qPCR and digital PCR were carried out and allowed to show a slight but not significant 
ZDHHC15 downregulation in SMS2 cDNA from peripheral blood. Since 3’UTR can be target of several 
miRNAs playing a role in mRNA regulation, was investigated if in SMS2 the c.*182A>C variant might have 
altered the normal target region of any miRNAs. Bioinformatic tools enable to select two miRNAs 
predicted to interact specifically with wild type ZDHHC15 3’UTR (miR-142-5p and miR-5590-3p) and 
three specifically with mutated ZDHHC15 3’UTR (miR-922; miR-191-5p and miR-4797-5p). Luciferase 
assay on HEK293T validated a specific and significant effect on wild type ZDHHC15 3’UTR sequence for 
miR-5590-3p and on mutated ZDHHC15 3’UTR sequence for miR-4797-3p, supporting the initial 
hypothesis of a possible transcriptional alterations due to A>C transversion. 
The identification of two different alterations on ZDHHC15 regulatory regions in two unrelated cases in 
such small cohort of SMS-like patients further supported the possible direct or indirect involvement of 
ZDHHC15 in RAI1 pathway.  
To test in vitro whether a transient knockdown of RAI1 and ZDHHC15 would lead to change in 
expression of genes associated to the regulation of circadian rhythms we used silencing experiments on 
human BE(2)-M17 neuroblastoma cell line. Both RAI1 and ZDHHC15 silenced cells displayed significant 
deregulation of expression in up to half of the circadian genes. Moreover, nine out of main sixteen 
circadian gene proteins tested were predicted to be palmitoylated supporting an eventual role of 
ZDHHC15 in circadian rhythms control. In silico palmitoylation predictions and silencing experiments 
corroborate the idea of interconnection among RAI1, ZDHHC15 and circadian rhythms, but further 
analysis are needed to get a mechanistic insight.  
In conclusion the combined genomic and functional approach used, highlight ZDHHC15 as a promising 
candidate gene involved in SMS/SMS-like phenotypes. 
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1.1_Smith Magenis Syndrome 
 
1.1.1_Clinical overview 
Smith Magenis Syndrome (SMS, OMIM#182290) is a sporadic dominant disorder, with an 
estimated prevalence of 1:15000-25000, described for the first time by Smith ACM et al. in 
1986 (Smith et al 1986). SMS results mainly from haploinsufficiency of RAI1 gene due to either 
17p11.2 deletion or RAI1 mutation, males and females are equally affected (Edelman et al 
2007). 
SMS has a clinically recognizable phenotype characterized by distinct physical features, 
neurodevelopmental delay, cognitive impairment and behavioural problems. SMS patients 
show peculiar craniofacial appearance, that usually progress with age, such as brachycephaly, 
midface hypoplasia, broad square-shaped face, and tented upper lip (Fig.1A-E) (Patil, Bartley 
1984; Smith et al 1986; Smith et al 1991; Moncla et al 1991). Moreover they are characterized 
by skeletal features, including brachydactyly (Fig.1F-G), short stature and scoliosis, and 
otolaryngologic problems represented by hearing loss, chronic ear infections and hoarse deep 
voice (Greenberg et al 1996; Smith et al 2002) (Tab.1). 
SMS individuals manifest a variable degree of intellectual disability along with a reduced 
sequential processing ability, short term memory and motor and speech delays. Behavioural 
features, reported in 75-100% of SMS cases, include remarkable sleep disturbance, 
stereotypies, maladaptive, self-injurious behavior and sensory processing issues. Despite these 
behavioural aspects represent pathognomonic signs of SMS disease generally are not 
recognized until age 20 months or older and evolve until adulthood (Dykens, Smith 1998; Smith 
et al 1998; Smith et al 1998; Sarimski 2004; Gropman et al 2006; Elsea, Girirajan 2008; Elsea, 
Girirajan 2011). 
The lack of a striking infancy/early-childhood facial phenotype (Fig.1A-C) and behavioral issues 
make SMS diagnosis challenging and usually delayed to schooling age. Brachycephaly, broad 
forehead, upslanting palpebral fissures, short upturned nose, tented upper lip vermilion with 
mild micrognathia emerged in primary school ages (Fig.1A). At early school age deep-set eyes 
and midface retrusion crop up (Fig.1B-C) resulting in easily noticeable prognatism throughout 
adolescence (Fig.1D-E). Maladaptive behaviors escalate with age and are usually related to 
developmental delay, associated systemic disorders and sleep disturbance degree (Dykens, 
Smith 1998; Elsea, Girirajan 2008; Elsea, Girirajan 2011). 
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Fig. 1 (A) SMS Female with 17p11.2 deletion, age 9 months (B) SMS male with 17p11.2 deletion age 30 months, 
(C) SMS male with 17p11.2 deletion age 4 years; (D) SMS female with RAI1 mutation, age 12 years; (E) SMS 
female with 17p11.2 deletion, age 15 years. (F-G) Hand and feet brachydactyly in a SMS patient (Elsea, Girirajan 
2008; Williams et al 2010) 
Tab.1 Clinical Features of Smith-Magenis Syndrome 
Frequency System Finding 
>75% of individuals 
Craniofacial / Skeletal 
Brachycephaly 
Midface retrusion 
Relative prognathism with age 
Broad, square-shaped face 
Everted, "tented"vermilion of the upper lip 
Deep-set, close-spaced eyes 
Short broad hands 
Dental anomalies (missing premolars; 
taurodontism) 
Otolaryngologic 
Middle ear and laryngeal anomalies 
Hoarse, deep voice 
Neurobehavioral 
Cognitive impairment/developmental delay 
Generalized complacency/lethargy (infancy) 
Infantile hypotonia 
Sleep disturbance 
Inverted circadian rhythm of melatonin 
Attention seeking 
Attention deficit (+/-hyperactivity) disorder 
Tantrums, behavioral outbursts 
Impulsivity 
Stereotypic behaviors 
Self-injurious behaviors 
Speech delay 
Hyporeflexia 
Signs of peripheral neuropathy 
Oral sensorimotor dysfunction (early childhood) 
Sensory processing issues 
  
  
Hearing loss 
  Short stature 
  Scoliosis 
  Mild ventriculomegaly of brain 
Common Hyperaccusis 
(50%-75% of individuals) Tracheobronchial problems 
  History of constipation 
  Abnormal EEG without overt seizures 
  Autism spectrum disorder (ASD) 
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Cardiac defects 
Less common Thyroid function abnormalities 
(25%-50% of individuals) Seizures  
  Immune function abnormalities (esp. low IgA) 
  
  
Renal/urinary tract abnormalities 
Occasional Seizures 
(<25% of individuals) Forearm abnormalities 
  Cleft lip/palate 
  Retinal detachment 
 
Sleep disturbance represents a hallmark of this syndrome and polysomnography and actigraphy 
revealed a broad spectrum of sleep anomalies including/comprising difficulty falling asleep, 
decreased or increased REM, multiple awakening and overall reduction of total sleep timing 
(Boone et al 2011). Sleep disturbance results in >90% of cases from an inverted circadian 
rhythm of melatonin (Fig.2). 
  
 
 
 Fig.2-Melatonin rhythmicity is altered in RAI1 mutated patients. Levels of urinary6-sulfatoxymelatonin (aMT6s), 
a surrogate for serum melatonin concentration, were determined over one day and normalized to urinary 
creatinine (Cr). A) In healthy individuals, the highest concentration of aMT6s is found in the first morning 
sample, reflecting the normal rise of serum melatonin during the night. B-C) This rhythmicity is inverted in RAI1 
mutated patients (B), similar to individuals with the SMS common deletion (C) Both children (top panel) and 
adult (bottom panel) are represented. Shaded areas indicate the period of darkness. RAI1, RAI1 mutation; Del, 
common SMS deletion (Boone et al 2011).  
  
A single study of SMS cases treated with oral β1 antagonist acenbutolol triggers the suppression 
of daytime melatonin peaks and a subjective behavioural amelioration, while melatonin 
nocturnal plasma concentration did not improve (De Leersnyder et al 2001). Further studies 
showed that administration of acenbutolol to reduce daytime melatonin secretion in 
combination with an evening oral dose of control-release melatonin to restore nocturnal 
plasma melatonin levels, subjectively improving behaviour (De Leersnyder et al 2003). 
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Nevertheless two patients displaying a normal melatonin secretion were reported recently 
(Potocki et al 2000; Boudreau et al 2009), thus positing that an aberrant melatonin secretion 
pattern might be just one of the contributors to sleep disturbance phenotype in SMS patients.  
 
1.1.2_SMS Overlapping Syndromes 
Together with delayed onset of a clear craniofacial dysmorphism some overlapping syndromes 
make SMS diagnosis tricky. Indeed Smith-Magenis syndrome (SMS) might shift to differential 
diagnosis with some syndromes presenting developmental delay, infantile hypotonia, short 
stature, distinctive facies, and a behavioral phenotype including: Prader-Willi syndrome (PWS, 
OMIM#176270) Down syndrome, in the newborn period (OMIM#190685), Brachydactly Mental 
Retardation syndrome (BDMR, OMIM#600430), 2q23.1 deletion syndrome (OMIM#156200), 
and Kleefstra syndrome (OMIM#610253). 
2q23.1 deletion syndrome shares with SMS the main clinical features concerning 
developmental delay, language impairment, behavioural problems and a variable degree of 
intellectual disability (Wagenstaller et at 2007; van Bon et al 2010; Williams et al 2010 a). In 
particular >90% of patients with 2q23.1 deletion have developmental, motor and speech delays 
along with autistic behaviour; hence sleep disturbance, short stature and craniofacial anomalies 
are observed in ~70% of cases (Mullegama et al 2015 a).  
BDMR presents broad and heterogeneous clinical features depending on 2q37 deletion size 
(Wilson et al 1995; Giardino et al 2003; Villavicencio-Lorini et al 2013; Wheeler et al 2014; Jean-
Marcais et al 2015). Due to BDMR stricking similarity to SMS patients were misdiagnosed 
(Williams et al 2010 a). BDMR syndrome resembles SMS facial dysmorphism, brachydactyly, 
mild to moderate intellectual disability, sleep disturbance, self-injurious behaviour by altered 
pain sensitivity and obesity.  
A summary of both peculiar and common clinical traits are shown in Venn diagram below 
(Fig.3). Besides all two syndromes mentioned are also linked to SMS causing gene at molecular 
level (Williams et al 2010 b; Williams et al 2010 c; Mullegama et al 2015 a,b). The details will be 
described in the following paragraphs. 
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Fig. 3-Venn diagram showing overlapping and non-overlapping clinical features in SMS, 2q23.1 deletion and 
BDMR syndromes (patients pictures from Williams et al 2010 a).  
 
Intriguingly Potocki-Lupski (PTLS, OMIM#610883), a developmental disorder caused by 17p11.2 
reciprocal duplication (Brown et al 1996; Potocki et al 2000; Potocki et al 2007; Greco et al 
2008), shares with SMS several clinical signs but usually resulting in an overall milder phenotype 
(Potocki et al 2000; Potocki et al 2007). According to a systematic clinical evaluation study, PTLS 
main features are, along with developmental delay and cognitive impairments, hypotonia, 
failure to thrive (FTT), hyperactivity, anxiety, atypia, autistic traits, obstructive and central sleep 
apnea (Potocki et al 2007) and sleep deficiencies (Mullegama et al 2017) (Fig.4 bottom plot).  
The gestalt of two SMS and PTLS patients and their main clinical features over the years are 
shown by the figure below (Fig.4). 
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Fig. 4- Gestalt of Smith Magenis Syndrome (A-H) and Potocki-Lupski syndrome (I-P). SMS female (patient  BAB 
468) 7 months (A), 2 years (B), 9 years (C), 21 years (D). SMS male patient, 23 months (E), 3 years (F), 12 years 
(G), 17 years (H). Trends of key neurodevelopmental features in SMS throughout age groups (upper righ plot). 
PTLS female (patient BAB 1006) 8 months (I), 3 years (J), 10 years (K), 28 years (L). PTLS male (patient BAB 1690) 
6 months (M), 6 years (N), 10 years (O), 19 years (P). Trends of key neurodevelopmental features in PTLS 
throughout age groups (bottom right plot). Shaded area represents undetermined prevalence of the PTLS 
features due to lack of data (Neira-Fresneda,  Potocki  2015). 
 
Both SMS and PTLS phenotype emerged with age (Neira-Fresneda,  Potocki  2015). As 
mentioned before SMS individuals, display frontal prominence, synophrys and prognathia (Fig.4 
upper left) while PTLS facial features, even if not considered really dysmorphic, consist of 
inverted triangle shape, down slanting palpebral fissures and relatively small jaw (Fig.4 bottom 
left). The developmental and behavioural concerns in PTLS as well as SMS seem to shuffle from 
infancy to early childhood. Cognitive impairment together with autism spectrum disorder 
15 
 
displays a similar trend in both syndromes (Fig.4 plots). Nevertheless among SMS cases autism 
spectrum disorder is variably represented.  
PTLS hyperactivity and SMS maladaptive behaviour seems to escalate from adolescence to 
adulthood (Fig.4 plots). Sleep disturbance seem to be peculiar of SMS (Fig.4 upper plot), but 
recently sleep anomalies are observed in PTLS patients too. Hence anxiety and atypia are 
usually reported in PTLS but not in SMS. Notably due to lack of data, the prevalence of PTLS 
features in adolescent and adult are not available (Fig.4 bottom plot).  
 
1.1.3_Molecular and genetic basis 
SMS is a syndromic congenital disorder due to either a 17p11.2 deletion encompassing retinoic 
acid-induced 1 (RAI1) gene or a mutation in RAI1. The 17p11.2 interstitial microdeletion 
accounts for 90% of SMS cases. A common 3.7 Mb deletion is the rearrangement found in 70% 
of cases (Shaw et al 2002), while the remaining 20-25% have smaller or larger deletions, also 
referred as atypical, spanning between 1.5 to 9 Mb. 
Recurrent 3.7 Mb microdeletions occur by an aberrant recombination mechanism between 
region specific DNA blocks (10-400 kb) with a >95% sequence identity known as Low-copy 
repeats (LCR) or paralogous Segmental Duplications (SD) (Stankiewicz, Lupski 2002), 
representing almost 5% of our genome.  
SD can be inter-chromosomal and intra-chromosomal depending on their chromosomal 
distribution. The inter-chromosomal LCR/SD are mainly located at either pericentromeric either 
subtelomeric regions, while intra-chromosomal LCR/SD are peculiar of a specific chromosome.  
Chromosome 17p11.2 is one of the highly rearrangement prone region due to the presence of 
intra-chromosomal SD mediating a Non Allelic Homologous recombination (NAHR) throughout 
meiotic crossover. Indeed, NAHR underlies common deletion observed in 70% of SMS cases. 
NAHR between SD typically results in two products, a deletion and a reciprocal duplication of 
SDs flanked region (Liu et al 2011) (Fig.5, bottom side). Three copies of a low–copy number 
repeats (LCRs), proximal, middle and distal SMS Repeats (REPs) (Fig.5), flank the SMS deleted 
region (Chen et al 1997), and two of them, the proximal and the distal SMS REPs, mediates a 
recurrent about 3.7 Mb deletion occurring by inter- or intra-chromosomal recombination. As 
expected NAHR mediates the reciprocal dup(17)(p11.2p11.2) including RAI1, and resulting in 
16 
 
Potocki-Lupski Syndrome. Noteworthy the incidence of reciprocal duplication remained under-
estimated due to both a detection limit and PTLS milder phenotype.  
 
Fig.5- Smith Magenis genomic region structure including RAI1 gene (yellow dot). 17p11.2 with proximal (SMS 
REP-P), middle (SMS REP-M) and distal (SMS REP-D) Repeats (upper side); Non Allelic Homologous 
Recombination occurring between proximal and distal REPs resulting in duplication, dup(17)(p11.2p11.2) and 
SMS  ̴4Mb deletion (bottom side). Different colored arrows represent three different REPs and their direction 
(modified by Potocki et al 2000; Elsea, Girirajan 2008).    
 
Diagnosis of SMS was based on a clinical suspicion and assessed by fluorescent in situ 
hybridization studies (Phenotype First approach), while PTLS diagnosis, as most of 
microduplication syndromes, is usually reached after a genome wide analysis (Genotype First 
approach) due to issues in assessing PTLS clinical diagnosis. Indeed, initially the number of SMS 
clinically reported cases was higher than PTLS (~300 versus just 75 cases, respectively) (Zhang 
et al 2010). However, once array comparative genomic hybridization allowed an high resolution 
identification of genomic variants (i.e. microdeletions and microduplications) genotype-
phenotype correlation arose and enabled PTLS patients description (Brown et al 1996; Potocki 
et al 2000; Potocki et al 2007). 
The genomic instability of 17p11.2 results from the prevalence of several repetitive elements 
such Alu elements and AT-rich repeats. Hence, the remaining 20-25% of SMS cases display 
atypical deletions, either larger or smaller than 4Mb, 50% due to NAHR and 50% mainly due to 
Non Homologous End Joining (NHEJ) (Shaw et al 2004; Shaw et al 2005). Thus corroborates the 
idea of 17p11.2 as a complex-rearrangement keen on genomic region as shown in Fig.6.  
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Furthermore, 17p11.2 deletion is typically a de novo event, but some familial cases has been 
observed, for instance, due to a mosaic condition in the mother (Zori et al 1993; Campbell et al 
2014).  
 
Fig.6- Chromosome 17p non-recurrent rearrangements. Proximal 17p complex genome architecture with several 
LCRs. LCR are represented by filled color-coded rectangles, hatch pattern and arrows define the orientation. The 
location of RAI1 gene and isochromosome 17q breakpoint cluster regions are highlighted. The upper side shows 
the region involved in SMS patients with atypical rearrangement, arrowheads indicate breakpoints. The bottom 
side shows the 17p11.2 breakpoints of translocations and the regions contained in the supernumerary marker 
chromosome (SMCs) (Lupski, Stankiewicz 2005).    
 
Although dissecting the different-sized SMS deletions a common overlap region of 1.5 Mb 
within 17p11.2 emerged (Slager et al 2003; Vilboux et al 2011). Several known genes were 
included in this 1.5 Mb critical region and for long time SMS has been considered a contiguous 
gene syndrome (Greenberg et al 1991). Subsequent sequence analyses of three patients with 
SMS phenotype, lacking the common deletion, identified frame-shift mutations on RAI1 gene 
(Slager et al 2003). Further studies reveal missense, non- sense and in-frame mutations mostly 
located on exon 3 (Fig.7) and affecting all transcript isoforms, thus making RAI1 SMS causing 
gene (Slager et al 2003; Bi et al 2004; Girirajan et al 2005; Bi et al 2006; Elsea, Girirajan 2008; 
Truong et al 2010; Vieira et al 2012). 
 
Fig.7- RAI1 exon 3 mutations hotspot. RAI1 gene structure with non-coding (red blocks) and coding regions 
(black blocks). All reported mutations are represented (Adapted from Elsea and Williams 2011). 
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Among patients with classical SMS clinical features with no 17p11.2 deletion, 10% of cases 
showed frame-shift and/or truncating mutations in RAI1 (Slager et al 2003). As shown in Tab.2, 
most of SMS clinical features are observed in similar percentages in both 17p11.2 deleted and 
RAI1 mutated patients. Although short stature, hearing loss, cardiovascular and renal 
malformation, and obesity resulted differentially represented in patients with 17p11.2 deletion 
and RAI1 mutation.  
  
Tab.2- Summary of SMS clinical features, percentages got by data published previously (Elsea, Girirajan 2008). 
Two columns highlight that most of the signs are equally represented independently of genetic variants 
underling the SMS phenotype.  
 
Diagnostic iter to detect SMS deletion classically goes through high-resolution karyotype 
analysis by G-banding and fluorescent in situ hybridization, while multiplex ligation-dependent 
probe amplification, a-CGH and real-time PCR allow the identification of smaller 
rearrangements. If no deletions are detected RAI1 Sanger sequencing is used to assess putative 
RAI1 mutation (Elsea, Girirajan 2008). 
Notably just 50% of patients with a clinical suspicion of SMS get a molecular diagnosis (Elsea, 
Williams 2012). Thus it is likely that other loci may contribute to SMS or SMS-like phenotype. 
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1.2_Disease-causing gene 
 
1.2.1_RAI1 
Retinoic Acid Induced gene 1 (RAI1) is recognized as the disease-causing gene. The primary 
transcript for RAI1 (GenBank AY172136, AJ271790; NM_030665.3; NP_109590.3; 
OMIM*607642) is formed by six exons, generating an 8.5 kb mRNA and a 1906-amino- acid 
protein encoded by exons III, IV, V, VI (Fig. 7) (Toulouse et al 2003). RAI1 is a transcriptional 
modulator involved in cell growth/cell cycle regulation, bone and skeletal development, lipid 
and glucose metabolisms, embryonic development and neuronal differentiation, behavioural 
functions, and circadian activity (Girirajan et al 2009; Williams et al 2012; Huang et al 2016). 
Across vertebrates analysed RAI1 is an   ̴200 kDa protein containing conserved domains, an N-
terminal transcriptional activation domain (TAD) (Bi et al 2005), nuclear localization signal 
(NLS), polyglutamine and polyserine tracts, and a C-terminal chromatin remodelling plant 
homeodomain (PHD finger or ePHD/ADD (extended plant homeodomain/ATRX-DMNT3-
DNMT3L) domain (Fig. 8)) (Darvekar et al 2013; Tahir et al 2014). C-terminal domain seems to 
be crucial for nuclear localization of RAI1 protein (Carmona Mora et al 2012). Indeed, SMS 
patients with either C-term truncating either point mutations involving C-term site display a 
protein unable to reach nuclear compartments (Carmona Mora et al 2012).  
 
 
Fig.8- RAI1 protein organization: structural organization of RAI1 functional domains poyQ, TAD, NLS and 
PHD/ePHD-ADD in H.sapiens, M.musculus, X.tropicalis, X.laevis and D.rerio (Tahir et al 2014). 
 
Mus musculus protein displays the higher overall sequence and specific domain identity of 
~80% compared to human one. Two different species of frogs, X. tropicalis and X. laevis, share 
respectively 44% and 42% of sequence similarity with full length human RAI1 (Tab.3). Hence 
both frogs species show a 60% sequence similarity within the chromatin interacting ePHD/ADD 
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domain. Zebrafish (Danio rerio) even if the lowest, has a 27% sequence identity with human 
protein and shares almost 60% similarity by ePDH/ADD domain (Tab.3). These data strongly 
support an evolutionary conserved role of RAI1 throughout different species.  
 
Tab.3- Comparison of human RAI1 full-length protein sequence and major domains with mice, frogs and 
zebrafish (Tahir et al 2014) 
 
According to murine model studies (Bi et al 2005), Rai1 expression in brain and craniofacial 
tissues reflects its relevant contribution to their specific development (i.e. orofacial, neural 
crest and cartilage). Xenopus l. morphants show a reduced size of forebrain ventricle and 
anomalous nerve tracts likely due to reduced brain derived neurotrophic factor (BDNF) 
expression (Tahir et al 2014). Further functional analyses reveal a broad expression of Rai1 in 
post-mitotic neurons where it acts as a positive regulator of target genes. Rai1 interacts directly 
with chromatin, preferentially at active promoter and enhancer regions, of genes mainly 
related in circuit assembly and neuronal communication. Hence, different cell types sense Rai1 
loss differentially. Basically Rai1 does not play a general housekeeping function, mandatory for 
every cell type. Rather, Rai1 has more crucial role in certain cell, i.e. subcortical excitatory 
neurons, the major contributors of SMS phenotypes in mice (Huang et al 2016).  
Animal models support RAI1 direct involvement as a dosage sensitive gene accounting for most 
of the clinical signs of SMS and PTLS (Walz et al 2003; Walz et al 2004; Bi et al 2005; Walz et al 
2006; Girirajan et al 2008; Ricard et al 2010; Lacaria et al 2013). A growing number of 
structure/function and phylogenetic data and animal models corroborate RAI1 role as 
transcriptional modulator involved in neuronal growth and neurobehavioral regulation. 
 
1.2.2_Factors putatively regulating RAI1 expression 
Due to RAI1 role in brain development, its expression is higher in this tissue (Toulouse et al 
2003). Very few is known about its transcriptional regulation, but in a recent study two SNPs, 
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rs9907986 and rs4925102 in 5’UTR RAI1 were identified as eventual regulatory elements (Chen 
et al 2016). Indeed, the SNPs mentioned are supposed to corrupt the binding of DEAF1 
transcription factor and RXR-RAR receptor, respectively at RAI1 5’-upstream region, accounting 
for 30-40% of RAI1 expression variance in human prefrontal and temporal cortex (Chen et al 
2016). 
Regarding RAI1 post-transcriptional regulation no details are available from literature. Even 
though within the SMS deletion common overlap region of 1.5 Mb, SMCR5, Smith Magenis 
syndrome chromosome region candidate 5, a non-coding RNA is reported (Bi et al 2002), but its 
function on RAI1 modulation remain to be investigated.   
As mention before other syndromes show a phenotypical overlapping with SMS, i.e. 2q23.1 
deletion syndrome and BDMR syndrome (2q37 deletion), caused by MBD5 and HDAC4 genes 
haploinsufficiency respectively. Indeed, in a recent array CGH screening of 52 SMS-like patients 
displaying most of SMS clinical features but lacking either the typical SMS deletion either RAI1 
mutation, HDAC4 and MBD5 alterations were found (Williams et al 2010 a). Among 52 SMS-like 
cases, 2 of them have a 2q37 deletion already associated to BDMR, and other 2 of them a novel 
mutation on HDAC4 gene. Subsequent RT-qPCR on these 4 patients reveal that, either deletion 
including HDAC4 either HDAC4 mutation results in RAI1 transcripts downregulation (Williams et 
al 2010 b), supporting their possible connection and the overlapping phenotypes of SMS and 
BDMR syndromes. 
HDAC4 is a class IIa histone deacetylase, located on 2q37.3 chromosome, made of twenty-
seven exons, which raise a 1084 aa protein (NM_006037.3; NP_006028.2; OMIM*605314). 
HDAC4 regulates transcriptional program essential for synaptic transmission and information 
processing in the brain. These roles are accomplished by dynamic interactions with 
transcription factors and neuronal chromatin (Sando et al 2012). Even though it seems to be 
dispensable for neuroprotection, its truncated form  is stably retained in the nucleus of 
cultured neurons and able to abolish HDAC4 target genes expression (Sando et al 2012). Since 
BDMR patients show RAI1 downregulation, might be posited  that HDAC4 plays as RAI1 
transcriptional regulator. 
The second locus that when disrupted results in SMS-like phenotypes is at 2q23.1 and involves 
MBD5 gene (Williams et al 2010 a). Talkowski et al. in 2011 demostrated that 2q23.1 deletion 
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syndrome results from deletion in chromosomal region 2q23.1 including methyl-CpG-binding 
domain 5 (MBD5) or MBD5 gene specific deletions (Talkowski et al 2011). MBD5 is a member of 
the MBD family and it is expressed in human brain in two isoforms. Translation of exon 6-15 
yield the main protein isoform (Laget et al 2010). Unlike others MBD family members MBD5 
MBD domain accomplishes interaction with Polycomb repressive complex PR-DUB (Baymaz et 
al 2014). Mullegama et al. on 2015 assessed a downregulation of RAI1 in 2q23.1 deletion, thus 
supporting the idea that also MBD5 might exert a control on RAI1 transcription (Mullegama et 
al 2015 a).  
Hence further studies correlates MBD5 haploinsufficiency of patients lymphoblastoid cell line to 
downregulation of Clock Circadian genes (CCG) (PER1, PER2, PER3, NR1D2, CRY2) as well as 
RAI1, thus linking circadian rhythms impairment to RAI1 expression (Mullegama et al 2015 b).  
Besides, RAI1 has been genetically linked with schizophrenia (Toulouse et al 2003), autism 
related condition (Van Der Zwaag et al 2009), and resulted downregulated in multiple 
intellectual disability syndromes not directly associated with RAI1 mutations. This suggests RAI1 
might act as downstream effector in other neuropsychiatric conditions.   
 
1.2.3_RAI1: a chromatin reader 
A label-free proteomics approach (Eberl et al 2013) on mice tissue lysates identified a group of 
novel reader proteins that specifically recognize unmethylated H3K4. The new so called “RAI1 
complex” includes iBRAF (HMG20B) an High Motility Group-box protein that promotes MLL1-
mediated H3K4me3 installation, RAI1, PHF14 and TCF20/SPBP. 
Notably, as observed for RAI1, TCF20 and PHF14 are linked to neurodevelopmental disorders 
(NDD) and MLL1, an H3K4me writer that may participate in this complex interacting with iBRAF, 
is associated with an intellectual disability syndrome (Jones et al 2012). RAI1 shows >50% 
similarity with TCF20 gene, a transcriptional cofactor (Darvekar et al 2013). RAI1, TCF20 and 
PHF14 all share a putative methyl-histone recognition module PHD or extended PHD (ePHD), 
while iBRAF due to its High Mobility Group domain can bind DNA. Unlike typical chromatin 
regulatory complexes no histone-modifying enzymes seem to be within this complex. It is likely 
that according to iBRAF role in MLL1 recruitment, the whole complex act as a reader of 
combined histone modifications stabilizing MLL1 on specific chromatin areas. The RAI1 complex 
23 
 
binds to unmethylated H3K4 and repelled H3K4me3 (Eberl et al 2013). Basically the 
unmethylated status serves as a “sensor” to find yet-unmethylated and/or recently 
demethylated H3K4 residues on gene promoters, thus recruiting MLL1 to tri-methylate H3K4 
and prompt gene transcription.  
RAI1 complex seems to counteract/counterbalance the activity of a well-known repressor 
complex, LSD1-CoREST that negatively regulates neuronal differentiation removing histone 
modifications from neuron specific genes. Specifically iBRAF competes with LSD1-CoREST 
complex at neuronal gene promoter and/or prevents BRAF35 (its structurally related HMG-box 
protein belonging to LSD1 complex) sumoylation which is crucial for BRAF35 anti-
neurodifferentiation activity (Ceballos-Chavez et al 2012). Overall both the complexes show an 
activity dependent gene expression essential for learning and memory (Ebert et al 2013) and 
neuronal plasticity (Loebrich, Nedivi 2009). In a recent in-vitro study RAI1 was shown to interact 
directly with an intronic region 1kb upstream BDNF promoter in HEK293T cells, promoting the 
transcription of a luciferase reporter DNA containing this intronic region. Moreover, Rai1 
depletion decreases Bdnf expression in mouse hypothalamus and frog embryonic brain (Bi et al 
2005, Tahir et al 2014). These data suggest a tight involvement of RAI1 in BDNF transcription, 
which is a key factor for neuronal development and synaptic plasticity (Loebrich, Nedivi 2009). 
Finally, can be postulated that RAI1 might trigger an increased BDNF, then MLL1 is recruited at 
neuro-specific gene promoters to tri-metilate H3K4 (Fig.9). Thus activity dependent genes are 
transcribed.  
 
Fig.9-Model of neuronal activity dependent transcription activation (Modified by Garay et al 2016).   
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1.3_Circadian Clocks & Circadian Rhythms 
 
Circadian rhythms corruption is involved in SMS sleep disturbance phenotype. Williams et al. 
2012 demonstrated that RAI1 haploinsufficiency resulted in a significant impairments of core 
circadian genes expression pattern thus linking SMS sleep disturbance phenotype to a proper 
circadian component homeostasis (Williams et al 2012). 
Circadian rhythms are 24hrs based biological cycles that enable organisms to adapt their 
physiology to daily shifts from sunlight to darkness. In mammals the circadian system is 
hierarchically structured (Albrecht 2012). The light stimulus, as external environment input, is 
detected by retina, transmitted to hypotalamus suprachiasmatic nuclei “the pacemaker”, and 
spread/transferred to peripheral cells/tissues to elicit a response (Albrecht 2012) (Fig.10).  
Each cell contains its clock (Balsalobre et al 1998), thus individual oscillators has to be 
synchronized and tissues kept in stable phase-relationship with each other. Hence tissues 
represent an internal environment that in turn might give in information to the 
clock/pacemaker.   
 
 
Fig.10- Circadian system structure: input to the clock, clock mechanism and clock output. Upper side represents 
the division at cellular level, bottom side show the subdivision at systemic level (Albrecht 2012). 
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1.3.1_Molecular Clockwork 
The molecular mechanism that makes the clock work in mammals relies on cell-autonomous 
oscillator generated by a transcriptional-translational negative feedback loop with a critical 
delay between stimulus and response (Fig.11). The core clock genes CLOCK and BMAL1 encode 
for activators (positive elements, Fig.11), and PER1, PER2, CRY1 and CRY2 which encode for 
repressors (negative elements, Fig.11). 
 
 
Fig.11- Transcription feedback mechanism of core clock 
genes. Positive elements (i.e. CLOCK, BMAL1); negative 
elements (PER1, PER2, CRY1 and CRY2) (Tahakashi 2017). 
                                                                      
 
CLOCK and BMAL1 heterodimerize triggering the expression of “clock controlled genes” (CCG) 
plus their negative regulators, PER period proteins (PER1, PER2) and cryptochromes (CRY1 and 
CRY2) (Lowrey, Takahashi 2004; Emery, Reppert 2004). First half of the day is characterized by 
ascendant transcription of a large number of output genes, then repression by PER/CRY 
heterodimers and activator transcription is inhibited. The delay in-between these oscillation is 
guaranteed by post-translational modifications (Fig.11-12). Phosphorylation by Casein Kinases I 
family, CK1δε allow PER/CRY dimers translocation to the nucleus, where they repress their 
downstream targets (i.e. CLOCK/BMAL1) (Fig.12). At the end of circadian cycle the PER and CRY 
proteins are specifically ubiquitilated and degraded by proteasome enabling a next cycle to 
start (Gallego, Virshup 2007; Lowrey, Takahashi 2011; Preussner, Heyd 2016). 
 
 
Fig.12- CRY/PER negative transcriptional feedback. CK1δε phosphorilations of CRY/PER heterodimers allow 
nuclear translocation thus transcriptional repression of BMAL1/CLOCK. BMAL1/CLOCK repression is a clock 
output essential to trigger biological processes rhythms (Tahakashi 2017). 
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According to Ueda et al. 2005, CCG transcription is modulated by three motifs: E-box elements 
found in clock genes too, Nuclear Responsive elements (NRE) (Ueda et al 2002), and D-box 
elements (Ueda et al 2005) (Fig.13). Each of them has several regulators involved in the cellular 
clock machinery modulation and are classified in three groups: E-box regulators (i.e. CLOCK, 
BMAL1, PER1, PER2, PER3, CRY1, CRY2, BHLHE40, BHLHE41, NPAS2 and BMAL2); D-box 
regulators (i.e. DBP and NFL3); and RORE-box/NRE regulators (i.e. RORA, RORB, RORC, NR1D1, 
NR1D2). 
 
 
Fig 13- Three promoter motifs regulating clock controlled 
genes (CCG), direct regulation is represented by black 
arrow, indirect regulation by hatched line arrow (Abrecht 
2012). 
 
 
 
Neurodevelopmental diseases (NDDs) are often characterized by sleep abnormalities due to 
compromised circadian rhythms. SMS and its overlapping syndromes often display a sleep 
disturbance phenotype. As demonstrated by Williams et al. 2012 a downregulation of main 
circadian genes cluster in RAI1 silenced cell line was observed. In particular, both RAI1 silenced 
HEK293T and SMS patients fibroblasts display CLOCK, BMAL1, PER1 and CRY1 downregulation. 
Hence dose-dependent RAI1 knockdown in U2OS-B cells results in circadian period shortening 
and dampened BMAL1 expression, thus mimicking CLOCK silencing in vitro and further 
supporting a crucial role for RAI1 in circadian rhythms maintenance. Indeed, RAI1 activates 
CLOCK transcription binding  an enhancer element located at CLOCK intron 1 directly or within a 
complex (Williams et al 2012).     
Besides, circadian genes regulation is orchestrated by periodic relaxing and compacting of 
chromatin structure at gene promoters (Ripperger, Schibler 2006). Indeed, dis-regulation of 
histone methylation likely influences not only cognitive deficits but also sleep-related 
symptoms in NDDs. Reminiscent of activity-dependent gene expression described in the 
previous paragraph, H3K4 regulators associated with NDDs could be essential for circadian 
transcriptional program too.  
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A possible mechanistic model has been posited to explain RAI1 role in circadian rhythm (Fig.14). 
Acetylated MLL1 is recruited at circadian gene promoters by a putative RAI1-complex 
dependent mechanism, thus allowing circadian genes expression by tri-metilation of their 
promoters at H3K4. Methyl transferase activity of MLL1 is dynamically regulated by SIRT1 
dependent MLL1 de-Acetylation; de-acetylation of MLL1 K1130 and K1133 is supposed to 
attenuate transcription inhibiting MLL1 activity at promoters (Garay et al 2016).  
 
 
Fig.14- RAI1 and MLL1 in circadian gene expression model (Modified by Garay et al 2016). 
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AIM 
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Smith Magenis like syndrome (SMS-like) corresponds to every neurological disorder which 
clinically resembles Smith Magenis syndrome (SMS) but molecularly lacks the classical 
microdeletion at 17p11.2 encompassing RAI1 or mutation in this gene. The difficulty of a proper 
clinical diagnosis is also emphasized by the later manifestations of the disorders whose clinical 
traits become more evident during school age. Up to 50% of patients with a suspicion of SMS 
do not have SMS classical genetic defects, thus it is likely that at genomic level more than one 
locus is involved in the disorder and may be responsible for similar phenotypes. Actually neither 
detailed mechanistic insight into RAI1 pathway nor an alternative molecular diagnosis able to 
explain SMS RAI1 negative patients phenotypes are available. 
Patients with a clinical suspicion of SMS but without a molecular diagnosis should be 
considered for whole genome high throughput analyses; using array Comparative Genomic 
Hybridization (array CGH) as primary tool, it will be easy to identify Copy Number Variants 
(CNVs) potentially containing dosage sensitive genes that, when disrupted, lead to an SMS-like 
phenotype. 
The main goal of this project will be a genetic and functional investigation of candidate genes 
implicated in SMS-like clinical manifestation.  
In a pilot study, a cohort of 40 patients with a clinical suspicion of SMS but without 17p11.2 
classical microdeletion was selected. CNV yet unreported in healthy subjects according to the 
Database of Genomic Variants will be chosen. Functional analysis on the most promising 
candidate will be performed to assess its pathogenic role and its eventual involvement in SMS-
like phenotype throughout a direct or indirect link with RAI1 disease gene. 
This combined genomic and functional approach should shed light on still unknown pathways 
linked to RAI1, thus improving both molecular and clinical diagnosis of SMS/SMS-like 
phenotypes. 
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MATERIALS AND METHODS 
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3.1_SMS/SMS-like experimental flowchart 
The cohort of cases collected includes 40 SMS-like patients resulting negative to preliminary 
diagnostic flowchart (Fig.15). In detail, these patients were negative to 17p11.2 deletion (by 
FISH or low resolution array CGH), RAI1 mutation (Sanger sequencing), RAI1 microdeletion 
(MLPA), and RAI1 transcripts downregulation (RT-qPCR) (left side of flowchart, Fig.15). 
In order to identify CNV potentially containing dosage sensitive genes that when disrupted 
might lead to patient SMS-like phenotypes high resolution array CGH analysis was performed 
for all patients. This approach has become an important tool in the genomic evaluation of many 
CNV-associated diseases (Williams et al 2010 a). Since 50% of SMS patients do not have a 
molecular diagnosis it can be useful to identify new candidate genes possibly implicated in the 
same pathways of RAI1 and thus explaining SMS-like phenotypes. 
Genome scan was performed on patients and their parents, by oligo-aCGH Agilent 400K 
platform, including 420,288 oligonucleotide probes 60nmer long, with a 5 kb spacing on 
average and 20 kb resolution. CNV yet unreported in healthy subjects according to the 
Database of Genomic Variants (http://dgv.tcag.ca/dgv/app/home) were chosen. The detected 
submicroscopic gains or losses were then confirmed by parents analysis or, if necessary, by 
quantitative PCR.  
Meanwhile the phenotypical overlapping genes (i.e. MBD5 and HDAC4) have been screened for 
mutational analysis by Sanger Sequencing to rule out/switch to a differential diagnosis chance. 
The detailed experimental workflow is summed up above (Fig.15). 
 
Fig.15- Experimental workflow  
 
3.2_Ethical approval 
The study has been approved by Ethics Committee and all the patients included signed an 
informed consent. 
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3.3_DNA extraction  
Whole blood samples from each patient and their relatives (when available) were collected by 
EDTA tubes (Beckton Dickinson) and extracted according to GenEluteTM Blood Genomic DNA kit 
protocol (Sigma Aldrich). The DNA was then quantified by NanoDrop (NanoDrop1000, 
Thermofisher Scientific) and stored at -20C°. 
3.4_HUMARA assay 
Genomic DNA of each individual was amplified in the Human Androgen Receptor (HUMARA) 
locus on X chromosome, either without enzymatic digestion (Undigested DNA) and after 
digestion with HpaII (HpaII digested DNA). The presence of two X chromosomes with a different 
number af CAG repeats inside HUMARA alleles results in the generation of two amplicons 
represented by the peaks. Amplicon size is indicated in bp. The 275 bp amplicon identifies the X 
chromosome allele that is inherited within the family. The X Chromosome Inactivation (XCI) 
percentage is established after the digestion with HpaII. In women only one of the two X 
chromosomes is active, thus HpaII sites are susceptible to digestion and PCR fails to amplify 
such allele giving a smaller peak than its undigested counterpart. Peak height is indicated in 
Relative Fluorescence Units (RFU). Quantification of peaks heights by GeneMapper software 
was used to calculate XCI percentage after digestion. As control, the patient DNA with only one 
active X chromosome is completely digested by HpaII and gives no amplification. Skewed or 
random XCI is defined using an arbitrary cutoff of 70-75% of cells with the same X inactivated. 
3.5_PCR 
The entire 3’UTR and coding regions of ZDHHC15 and at least 30 bp of the flanking intronic 
sequences were amplified by polymerase chain reaction (PCR) using AmpliTaq Gold (Applied 
Biosystems) or Kapa2G Robust PCR Kit (KAPABiosystems). Amplification primers are shown in 
Tables below (Tab.4-5). 
Tab.4- ZDHHC15 primers 
GENE Exon  Primer sequence (5'→3') Amplicon size (bp) Annealing Temp (°C) 
 
1 Fw: GCTCCAACATGGCTAGTTCC 438 59 
 
 
Rev: AAGGGACACCAGTGTGAAGG  
  
 
2 Fw: CTTGCCTTCCCTCATCTTTG 301 56 
 
 
Rev: TGGGAAAATTGCTCGGTCTA 
  ZDHHC15 3 Fw: TGGCTTGTTTCTGTCACTGTATG  346 58 
  
Rev: CCTCTTTTTGTCCTCTTCTTGC  
  
 
4 Fw: CCTGAGCTTCAAGGGTAGGT  347 58 
  
Rev: GGTTTTCAGAAGATGGGAGGA 
  
 
5 Fw: TGTAGTCTGCCTTTTGCTTGG 361 57 
  
Rev: GTGTGAGGGGTTTTGGCATA 
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6 Fw: GGCCACAGTTTTGGAGTCAC  335 59 
  
Rev: AATGTTACCCCTCCCCTGTC 
  
 
7 Fw: CGACACATAATGAAGCAGCAG  295 58 
  
Rev: CACAAGTTGGAGTGGGTGTG  
  
 
8 Fw: AGCACACTCACAGGTATCATCA  372 59 
ZDHHC15 
 
Rev: CACAGGTCCCTCTGATACACA 
  
 
9 Fw: TGTGCTACCACAGCAAAAAGA 355 56 
  
Rev: TGGACTGATACCTGCTGCAT  
  
 
10 Fw: CCATTCCACCATGGCTTTAG 355 58 
  
Rev: CCACCATCCAGAGGACACTT  
  
 
11 Fw: TCTGTTGCCTGCAGAGATTG 360 56 
  
Rev: CACACTGCCAAGGGAAATTA  
  
 
12 Fw: CAAGTGGGTGTTACCACATGA 455 56 
 
  Rev: TCCCTTCAACACCAAAAAGG 
   
Tab.5- ZDHHC15 3’UTR primers 
GENE 3' UTR fragment Primer sequence (5'→3') Amplicon size (bp) Annealing Temp (°C) 
 
1 Fw: TTGCTGTGTAAATGTTTCTGGA 313 56.5 
 
  Rev: GCTGTACGTGTTCACAAATGC 
  
 
2 Fw: CCCAATCCATGAAAGCCTAA 438 56.4
 
  Rev: CTGTGGTGCTTTCAGGAACA 
  
 
3 Fw: TTTGAATCATCGCTATATCAAGTATC 591 56.7
 
  Rev: TCTGAAAACCCTTAACAAAACC 
  
 
4 Fw: GGGTGCAGTAAAATTCTCCAA 592 55.1
 
  Rev: ATTAGTAAGCCAAACCATCCCTCT 
  
 
5 Fw: TTGCATCAATTTCCCCATTT 559 53.1
 
  Rev: TTGAAACCCAGTGTGTGCAT 
  
 
6 Fw: TGACCAAGGTGAGACTTTTGG 502 57.5
 
  Rev: TTGACTTCTGTGGGAGCTGA 
  ZDHHC15 7 Fw: CATCTTCTGCCAAGCATTCA 578 56.2
 
  Rev: CCCCTGGTAAAACCCTGATT 
  
 
8 Fw: GGAGTGTTGGTGCATGACTG 518 58.2
 
  Rev: TGACATAGCACCCTTCAGCA 
  
 
9 Fw: TGGATCCCTGTCCAATAACC 619 58.2
 
  Rev: ATGGGGCTAGTAGGGGAAAG 
  
 
10 Fw: CAGGATCACATTCTGAAAGAGTCA 601 57.5
 
  Rev: TGTTCTTCACATGCTGTGTTTC 
  
 
11 Fw: CATACACATTTTCTCCAAAGCA 512 55.8
 
  Rev: TGCTGATGGCTGTGTACCAT 
  
 
12 Fw: CCATATTAAATTGTAGCCTTTTGC 499 56.3
 
  Rev: CGCATACCAATCAACCTGAG 
   
3.6_Sanger Sequencing, Sequence purification & alignments 
The PCR products were subsequently column purified by IllustraTM GFXTM PCR DNA and Gel 
Band Purification Kit (GE Healthcare) to remove unincorporated primers and dNTPs, and then 
sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems). 
Sequence were purified by Centri-Sep kit (Princeton Separation) and run on Genetic Analyzer 
3500 capillary sequencer (Applied Biosystems). All sequence were aligned by ChromasPro 
software to a wild type (WT) sequence. Detected variants were analyzed by Ensembl 
(https://www.ensembl.org/) and dbSNP (https://www.ncbi.nlm.nih.gov/projects/SNP/) 
databases.  
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3.7_RNA extraction 
Each blood sample has been collected in Tempus Blood RNA Tubes (Applied Biosystems) and 
processed according to Tempus Spin RNA isolation Reagent Kit (Applied Biosystems). The RNA 
was then quantified by NanoDrop and stored at  -80°C until used. 
3.8_RT-qPCR 
Retrotranscription of 500-800 ng of total RNA samples extracted from whole blood of either 
patients either controls was performed using High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystem). Quantitative Real-Time PCR has been performed using RAI1 TaqMan 
probe (Hs01554690_m1) and ZDHHC15 TaqMan probe (Hs00327516_m1). All samples were run 
in triplicate processed by ABI PRISM 7900HT and normalized to GAPDH TaqMan probe 
(Hs99999905_m1), TBP TaqMan probe (Hs00427620_m1), RPLP0 (Hs99999902_m1) and HMBS 
TaqMan probe (Hs00609297_m1). Differences in transcripts levels quantified by 2-ΔΔCt method. 
Statistical analysis applied was One Tailed Student T-test. 
3.9_Digital PCR 
Digital PCR analysis has been performed thanks to a collaboration with Humanitas Research 
Center. 
3.10_Protein extraction from peripheral blood 
Leucocytes fraction has been isolated from each blood sample using CPT vacutainer (Beckton 
Dickinson). The cell pellet was then washed with ice cold PBS and lysed by RIPA buffer (50mM 
Tris HCl pH 7.4; 1% NP40; 0.5% Na-deoxycholate; 150mM NaCl; 1mM EDTA; 0.1% SDS) plus 
cOmplete protease inhibitor cocktail (Roche) added just before use. All the RIPA whole cell 
extracts were stored at -20C°.  
3.11_WB analysis 
 RIPA extracts were loaded on Novex® Tris-Glycine 4-12% acrylamide gel (Thermofisher 
Scientific), semidry transferred on iBlot® transfer stacks by iBlot®transfer device (Thermofisher 
Scientific) and immunoblotted with GAPDH ab (NB300-320), ZDHHC15 ab (NBP1-82014). Bands 
revealed by respective secondary antibodies (peroxidase-mouse anti-goat 200-035-308, 
Jackson Immunoresearch; goat anti-rabbit ab6721) after 5 mins incubation with Luminata 
Classico (Millipore). 
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3.12_HEK293T: culturing methods 
HEK293T cells were grown in Dulbecco’s Modified Eagles Medium (DMEM) supplemented by 
10% Fetal Bovine Serum (FBS, Sigma), 1% penicillin/streptomycin, 1% glutamine and 1% sodium 
pyruvate at 5% CO2. HEK293T were maintained according to specific cell line requirements. 
3.13_Plasmids creation & selection for luciferase reporter assay 
 Both ZDHHC15 3’UTR wild type and mutated sequences (321 bp) have been amplified by PCR 
with specific primers, ZDHHC15 forward 5’-CCTCCCATGAGGCTTACAGA-3’ and ZDHHC15 reverse 
5’-GGGGGAATTAAAGACTCTAAGGA-3’ at 58.9°C annealing temperature using as templates 
respectively a control patient DNA and DNA from patient with ZDHHC15 3’UTR transversion. 
Both amplification products were subsequently cloned by TOPO® TA Cloning® Kit  into 
Topo®TA® plasmid (pCR™II-TOPO® vector) according to manufacturer protocol (Thermofisher 
Scientific). After transforming by heat shock procedure E.coli positive colonies selected by 
IPTG:X-Gal were picked and the insertion direction of fragments was verified by DNA 
sequencing using BigDye kit (Applied Biosystem). Plasmids isolation was performed by midi 
prep procedure (Qiagen) and TOPO-TA plasmid constructs were enzymatically digested by SacI 
and XbaI. Then wild type and mutated ZDHHC15 3’UTR sequence were SacI and XbaI  cloned 
into pmirGLO dual-luciferase vector (Promega) at 3’ end of the firefly gene. All clones and their 
orientation were validated by DNA sequencing as above. 
3.14_miRNAs selection 
Different prediction softwares, i.e. miRdb (Wang, El Naqa 2008), DIANA (Kirakidou et al 2004), 
miRanda (John et al 2004), Target Scan (Lewis et al 2005), miRdb custom, Find Tar3 and 
RNAhybrid (Rehmsmeieret et al 2004) were used to select miRNAs putatively interacting with 
ZDHHC15 3’UTR. In particular miRdb (http://mirdb.org), DIANA (http://diana.cslab.ece.ntua.gr/) 
miRanda (http://www.microrna.org) and Target Scan (http://www.targetscan.org) tools enable 
to choose miRNAs interacting with ZDHHC15 3’UTR wild type sequence. Whereas miRdb 
custom (http://mirdb.org) and Find Tar3 (https://bio.sz.tsinghua.edu.cn/) allowing 3’UTR 
mutated sequence uploading, shortlisted miRNAs supposed to be specific for ZDHHC15 3’UTR 
mutated sequence. RNA hybrid (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid) has been 
used to validate the predictions for mutation specific miRNAs on thermodynamic and statistical 
modeling basis. All predictions were integrated with text mining to shortlist the most relevant 
miRNAs. 
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3.15_Co-transfection  
HEK293T cells were maintained in 12-well plates according to standard practice. Transfections 
with a final concentration of 250ng of wild type or mutated ZDHHC15 3’UTR pmirGLO 
constructs and 50nM of each specific miRNA, i.e. hsa-miR-142-5p, hsa-miR-5590-3p, hsa-miR-
4797-5p, hsa-miR-191-5p, hsa-miR-922 (qiagen) and miRIDIAN microRNA mimic negative 
control (Thermofisher Scientific) were performed with LipofectamineTM 2000 (Thermofisher 
Scientific) following manufacturer instructions. The cells were then incubated 24hrs at 37C° in 
5% CO2 before harvesting for luciferase assay. 
3.16_Luciferase assay 
After plasmid and miRNA co-transfection and 24hrs incubation, the samples were washed with 
Phosphate Buffered Saline (PBS) and lysed in recommended volume of Passive Lysis Buffer 
included in Dual-Luciferase® Repoter Assay Kit (Promega) following manufacturer protocol. 
Using a multi-sample luminometer (Fluoroskan Ascent FL, ThermoLabsystems) 20ul of each 
lysates was dispensed in 96-well plate, nunclon Delta white microwell SI (Nunc) and LAR II 
solution and  Stop&Glo® Reagents set up to be sequentially auto-injected by the device (i.e. 2 
seconds pre measurements delay followed by 10 seconds measurement period for each 
reporter assay). All the measurements were performed according to standard manufacturer 
protocol (Promega).  
The firefly luciferase activity of wild type and mutated ZDHHC15 3’UTR constructs was 
normalized against the renilla luciferase output of the same pmiRGLO construct. Normalized 
firefly luciferase activity was represented relative to miRNA negative control transfected cells. 
Statistical analysis applied was One Way Anova and Tukey post-hoc test.  
3.17_BE(2)-M17: culturing methods 
BE(2)-M17 were grown in Roswell Park Institute Memorial medium (RPMI 1640, Sigma Aldrich) 
supplemented by 10% FBS, 2% glucose, 1%Sodium Piruvate, 1% penicillin/streptomycin and 1% 
L-glutamine. BE(2)-M17 were maintained according to specific cell line requirements.  
3.18_Gene silencing  
BE(2)-M17 were maintained in 6-well plates according to standard practice. For gene silencing 
experiments the following siRNA duplexes were used: stealth RNAi Negative control medium 
GC as negative control (Thermofisher Scientific); 5’-GCUGCCGCUUGAGAGAACACUCAAA-3’ and 
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5’-UUUGAGUGUUCUCUCAAGCGGCAGC-3’ for RAI1_HSS116567 (Thermofisher Scientific); 5’-
GCUACCGGUUUACACAAGAACUGGA-3’ and 5’-UCCAGUUCUUGUGUAAACCGGUAGC-3’ for 
ZDHHC15_HSS136141 (Thermofisher Scientific). Cells were transfected twice, using  
LipofectamineTM 2000 (Thermofisher Scientific) with 80nM of the indicated siRNAs duplexes, 
once every 24hrs and harvested at different time points: 48hrs post the first transfection for 
siRNA against ZDHHC15 and its negative control, 96hrs post the first transfection for siRNA 
against RAI1 and its negative control.  
3.19_RNA extraction: Tri Reagent 
BE(2)-M17 cells transiently transfected were lysed and RNA was extracted by Tri Reagent® as 
described by manufacturer protocol (Sigma Aldrich). RNA obtained were resuspended in DEPC 
treated water, quantified by nanodrop and stored at -80C°.  
3.20_RT-qPCR 
Retrotranscription of 3µg of mRNA samples derived from ZDHHC15 and RAI1 silenced BE(2)-
M17 cells was performed using SuperScript II RT (Invitrogen).  Oligonucleotide pairs for each 
gene were designed with Primer3 4.0 software (http://bioinfo.ut.ee/primer3-0.4.0/primer3/) 
on exon boundaries. Primers sequences are listed in the table below. 
GENE Primer sequence (5'→3') Amplicon size (bp) 
HDAC4 Fw:TGAGTTCCAGAGGCAGCAC 83 
 
Rev: GCATCTCCTGTTGTTGCTTG 
 MBD5 Fw: CCAGTGATACCAAACAGCATTG 86
 
Rev: ATGGCTATGGAGGATGATGG 
 SIRT1 Fw: CCTCCTCATTGTTATTGGGTCT 80
 
Rev: GAGGCACTTCATGGGGTATG 
 ZDHHC15  Fw: CTGGAAGTGGAGCTGTACGA 87
 
Rev: CACACATAGCACAGACAGAGCA 
 RAI1  Fw: AAAGGGAGACGGCGAGAC 78
 
Rev: CATGACTCGGGCTGGTTATC 
 CLOCK Fw: TGCACTGTTGAAGAACCCAAT 86
 
Rev: GGTGGTGCCCTGTGATCTA 
 BMAL1  Fw: GCGGCTCATAGATGCAAAA 84
 
Rev: CGTCGTGCTCCAGAACATAA 
 BMAL2 Fw:TGGATGCTTACCCAACTCAA  84
 
Rev: GGAGGCCAGCTTCTCAAGTA 
 PER1 Fw: TCTGCCGTATCAGAGGAGGT 87
 
Rev: CCCGGATCTTGGTCACATAC 
 PER2 Fw: CATGTGCAGTGGAGCAGATT 94
 
Rev: TTCATTCTCGTGGCTTTTCC 
 PER3  Fw: CGGTTACAGCAGCACCATT 78
 
Rev: GTCCAGGGCTCACAGAAGAG 
 CRY1  Fw: CAGGTTGTAGCAGCAGTGGA 66
 
Rev: TGTCGCCATGAGCATAGTGT 
 CRY2  Fw: AGGGAGGAGAGACAGAAGCTC 100
 
Rev: AGGGAGTTGGCGTTCATTC 
 NR1D1  Fw: ACAACACAGGTGGCGTCAT 76
 
Rev: TAGAGGGATTCAGGGCTGGT 
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NR1D2  Fw: AGGCTGTAAGGGTTTCTTTCG 70 
 
Rev: TTCATTCTTCAGGCACTTCTTG 
 FBLX3  Fw: AGCTACCCATCCAGAGCTGA 97 
 
Rev: AGCTGATTCCTTGCTGCTGT 
 CSNK1D Fw: CAAAACCGTCCTGCTGCT 99 
 
Rev: AGGAAGTTGTCTGGCTTCACA 
 CSNK1E  Fw: CGTCTTTGACTGGAACATGC 90 
 
Rev: CTCTCCTCGCGTTCGTGT 
 RORC  Fw: GTCCCGAGATGCTGTCAAGT 77 
 
Rev: GCTGTTTCTGCACTTCTGCAT 
 RPL10a  Fw: GAAGAAGGTGTTATGTCTGG 57 
 
Rev: TCTGTCATCTTCACGTGAC 
  
Quantitative Real-Time PCR was performed for 40 cycles with SYBR Green PCR Master mix 
(Applied Biosystems) and processed on ABI PRISM 7900HT (Applied Biosystems). Reactions 
were run in duplicate for each sample and a dissociation curve was generated at the end. 
Threshold cycles (Ct) for each tested gene were normalized on the housekeeping RPL10a gene 
value (ΔCt) and every experimental sample was referred to its control (ΔΔCt), fold change 
values were expressed as 2-ΔΔCt. Statistical analysis applied was One Tailed Student T-test. 
3.21_CSS-Palm 4.0 software: palmitoylation prediction software 
CSS-Palm software (http://csspalm.biocuckoo.org/online.php) allows palmitoylation prediction 
of target proteins by a clustering and scoring algorithm (Zhou et al 2006). Fasta sequence of 
each protein of interest has been used to predict eventual palmitoylation sites. In silico  analysis 
was performed with a medium threshold. The results obtained are summarized in tabs.    
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4.1_Preliminary data  
Among 40 SMS-like patients array CGH analysis on blood extracted DNA identified a CNV, 
specifically a deletion on Xq13.3 (chrX:74772380-74826319, hg19) in one male patient (SMS1) 
inherited from his healthy mother (Fig.16). 
 
Fig.16- High resolution 400K array CGH analysis (Agilent technology) identified a rare 54 kb deletion in Xq13.3 in 
SMS1 (chrX:74772380-74826319, hg19). 
Patient SMS1 carrying the Xq13.3 deletion is a boy aged 4 years, born from healthy non-
consaguineous parents, who came to the attention of the medical geneticist for a suspected 
genetic syndrome. Clinical evaluation showed in the proband mild craniofacial anomalies such 
as brachycephaly, square face, thick eyebrows, hypertelorism, and broad palate. Brachydactyly 
of hands and feet was also noted, as well as generalized hypotonia, developmental delay, 
behavioural problems (self-injurious), sleep disorders and congenital heart defect that was 
surgically corrected at age of 1 year. Based on SMS1 clinical evaluation SMS-like suspicion was 
assessed and according to preliminary diagnostic flowchart (Materials and Methods, fig. 15), 
17p11.2 deletion and RAI1 sequence mutation were excluded. Moreover, SMS1 RAI1 levels 
resulted normal compared to ten healthy controls with both TBP and GAPDH housekeeping 
genes used to normalize the samples (Fig.17).  
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Fig.17- RT-qPCR of RAI1 expression on SMS1 and ten healthy controls (C1-C10), C1-C5 are female controls, C6-
C10 are male controls. RT-qPCR was performed twice using two different housekeeping genes, GAPDH and TBP. 
 
Array CGH analysis, extended to healthy grandparents and healthy uncle both on mother side, 
showed that the rare Xq13.3 deletion was not present in the males of the family analyzed but 
inherited from the grandmother (Fig.18), supporting a possible pathogenic role of this CNV. 
 
Fig.18- Pedigree representing the inheritance of the CNV identified in SMS1 (filled symbol and highlighted by 
arrow) among the four generations (I, II, III and IV). Both his healthy mother and maternal grandmother bear the 
same rearrangement (spotted circles). Array CGH results are indicated for the relatives analyzed.  
Human Androgen Receptor (HUMARA) Assay was then used on DNA from peripheral blood 
lymphocytes to establish the X inactivation pattern in the females of SMS1 family bearing the 
Xq13.3 deletion. The analysis revealed a skewed X inactivation in the mother (73%-27%) and a 
random one in the grandmother (38%-62%) (Fig.19). Notably, the skewed allele (275 bp) is the 
one transmitted to SMS1. 
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Fig.19- HUMARA assay results. A) Schematic family pedigree showing segregation of the amplified X 
chromosome allele (275 bp) among the three represented generations (I, II and III). Lines in bold indicate the 
segregation of the trait in the family; dotted empty squares represent not analyzed males. B) Electropherograms 
resulting from HUMARA assay. The 275 bp amplicon identifies the X chromosome allele that is inherited in the 
family (higher peak). The X Chromosome Inactivation (XCI) percentage is established after the digestion with 
HpaII. Peak height is indicated in Relative Fluorescence Units (RFU). XCI percentage is reported under the peaks. 
Skewed or random XCI is defined using an arbitrary cutoff of 70-75% of cells with the same X inactivated. 
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4.2_CNV characterization: are there any genes involved in? 
The Xq13.3 deletion spans 54 kb and does not involve any gene but contains a highly conserved 
region and a predicted insulator (Fig.20). Notably the Xq13.3 deletion maps 29 kb far from the 
5’ end of ZDHHC15 (Zinc Finger DHHC domain-containing protein 15) (Fig.20) which encodes for 
palmitoyl-transferase 15 ubiquitously expressed, but highly expressed in the brain. Moreover, 
based on literature data, ZDHHC15 was found previously associated to a nonsyndromic X-linked 
intellectual disability (Mansouri et al 2005). 
 
Fig.20- Deleted region on chromosome Xq13.3 is shown by a red bar. UCSC view is represented below. The 
predicted insulator element is shown by light blue blocks (UCSC, Genome Browser; http://genome-
euro.ucsc.edu, hg19). 
 
According to these findings ZDHHC15 was considered an interesting gene possibly implicated in 
patient phenotype onset. Hence we hypothesized that the 54 kb deletion involving predicted 
insulator element might result in ZDHHC15 transcript alteration by a position effect. 
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4.3_Could a ZDHHC15 defect be implicated in the onset of the proband 
phenotype? 
 
4.3.1_Position effect evaluation by RT-qPCR  
To disclose an eventual pathogenic effect of the CNV identified we performed RT-qPCR analysis 
on peripheral blood RNA of SMS1 and his healthy mother looking for eventual ZDHHC15 
expression changes. RT-qPCR revealed a significantly reduced level of ZDHHC15 mRNA in SMS1 
patient when compared to nine healthy controls, while SMS1 mother ZDHHC15 levels are 
similar to controls level (Fig.21, upper panel). The RT-qPCR on SMS1 was then replicated two 
times with different housekeeping (i.e. TBP and HMBS) and confirmed a significantly ZDHHC15 
downregulation when compared to ten healthy male controls (Fig.21, bottom panel). 
 
 
 
Fig.21- RT-qPCRs analyses of ZDHHC15 expression on SMS1. Upper panel represents RT-qPCR performed on 
SMS1, his mother, five healthy male controls (C1-C5) and four healthy female controls (C6-C9), normalized on 
GAPDH gene. Bottom panel represents RT-qPCR performed on SMS1 and ten healthy male controls (C1-C10) 
normalized on TBP and HMBS genes. Student T test, *P<0.01. 
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4.3.2_Is ZDHHC15 a candidate gene? 
Findings obtained on SMS1 and ZDHHC15 association with X-linked intellectual disability (OMIM 
#300577, MRX91) prompted us to Sanger sequence ZDHHC15 in all SMS-like male patients of 
our cohort (n=13) to find out other possibly pathogenic variants that might support its 
involvement in SMS-like onset. Surprisingly, a second male patient (SMS2) with c.*182A>C 
genetic transversion on exon 12 (3’UTR of ZDHHC15) emerged (Fig.22).  
 
Fig.22- Electropherogram of patient SMS2 with ZDHHC15 3’UTR transversion and his parents. 
Even SMS2 mutation is rare, has been never reported among the databases analyzed (Ensembl, 
dbSNP, HGMD, ExAC browser) and maternally inherited. SMS2 shows together with cognitive 
developmental delays the following SMS clinical features: short stature, squared-shaped face 
and slight prognatia, brachydacthyly, behavioural issues and sleep deficiencies. As resulted in 
SMS1 patient, SMS known molecular defects were ruled out and RT-qPCR on SMS2 blood 
derived RNA to test RAI1 transcript levels resulted similar to ten healthy controls (Fig.23). 
 
Fig.23- RT-qPCR of RAI1 expression on SMS2 and ten healthy controls (C1-C10), C1-C5 are female controls, C6-
C10 are male controls. RT-qPCR was performed twice using two different housekeeping genes, TBP and GAPDH.  
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Since the transversion detected in SMS2 is on 3’UTR, which has a role in translation efficiency, 
location, and stability of mRNAs, we postulated that the variant might have an effect on 
ZDHHC15 transcript regulation or translation. To assess this potential effect on transcript we 
performed RT-qPCR analyses on blood mRNA of SMS2 and ten healthy male controls (Fig.24).  
 
 
     
Fig.24- RT-qPCRs of ZDHHC15 expression on SMS2 with ZDHHC15 3’UTR transversion and ten healthy male 
controls (C1-C10). Standard reactions are shown on the upper side, reactions with increased amount of cDNA on 
the bottom side. In both reaction series were used three different housekeeping genes, i.e. HMBS, TBP and 
RPLP0. 
 
RT-qPCR analyses were performed using different housekeeping genes (HMBS, TBP and RPLP0) 
initially according to standard amount of cDNA per reaction (12.5 ng). Normalized on HMBS and 
RPLP0, ZDHHC15 levels of SMS2 resulted similar to ten healthy male controls (Fig.24, upper 
side), whereas normalized on TBP (Fig.24, upper side) SMS2 ZDHHC15 mRNA expression 
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seemed slight downregulated. Notably ZDHHC15 mRNA resulted variably and poorly expressed 
in blood tissue, with high Ct values, thus affecting reproducibility and reliability of RT-qPCR 
data. To overcome this issue and clarify the suspicion of ZDHHC15 downregulation, the same 
RT-qPCR were replicated using an higher amount of cDNA (140 ng per reaction) for both SMS2 
and controls. The analyses supported the initial suspicion even if data were not statistically 
significant (Fig.24, bottom side). 
To corroborate RT-qPCR data an absolute ZDHHC15 quantitation on SMS1 and SMS2 blood 
extracted RNA was performed by digital PCR. SMS1 patient significant ZDHHC15 
downregulation was consistent with RT-qPCR data, while for SMS2 the suspicion of a slight 
ZDHHC15 was not clarified. Indeed SMS2 cDNA ZDHHC15 copies/microliter resulted within the 
control variability range, even if with the lowest value (Fig.25). 
 
 
Fig.25- Digital PCR results. SMS1 and SMS2 ZDHHC15 copies/microliter and ten healthy male controls (C1-C10) 
are shown. Student T test, *P<0.01.  
 
4.3.3_miRNAs and Luciferase assay: does 3’UTR variant have an effect? 
Since 3’UTR region is known to play a pivotal role in stability and regulation of mRNAs, we 
investigated whether specific miRNAs predicted to bind ZDHHC15 3’UTR might potentially 
modulate ZDHHC15 expression and in particular, we studied if the c.*182A>C variant could 
change or introduce new miRNA sites in ZDHHC15 3’UTR. To get a list of miRNAs putatively 
interacting with wild type ZDHHC15 3’UTR we used different bioinformatic tools such as, 
miRdb, DIANA,  miRanda, and TargetScan. These prediction softwares are based on 
complementarity but use different algorithms leading to different predictions. For this reason 
the resulting miRNAs list was not consistent switching from one tool to the other. Therefore we 
Sample Copies/ 
microliter 
CI copies/ 
microliter 
Precision 
SMS1 12,598 10.741 -- 14.777 17,29% 
SMS2 29,936 26.974 -- 33.223 10,98% 
C1 55,353 51.165 -- 59.885 8,19% 
C2 48,566 44.794 -- 52.656 8,42% 
C3 66,734 62.223 -- 71.572 7,25% 
C4 35,546 32.497 -- 38.88 9,38% 
C5 34,561 31.408 -- 38.03 10,04% 
C6 72,495 67.855 -- 77.453 6,84% 
C7 52,606 48.703 -- 56.821 8,01% 
C8 41,873 38.463 -- 45.584 8,86% 
C9 59,785 55.611 -- 64.273 7,51% 
C10 42,676 39.163 -- 46.504 8,97% 
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chose the miRNAs recurrent in at least two softwares, such as hsa-miR-142-5p and hsa-miR-
5590-3p (Tab.6). TargetScan revealed a specific pairing between seed sequence of these two 
miRNAs and the wild type ZDHHC15 3’UTR where our transversion occurred, thus further 
corroborating the in silico predictions (Fig.26).  
 
Tab.6. In silico predictions of miRNa binding site in the ZDHHC15 3’UTR sequence spanning the c.*182A>C 
(miRDB, Diana, miRanda, TargetScan). 
 
 
 
Fig.26-TargetScan output, pairing between hsa-miR-142-5p, hsa-miR-5590-3p and wild type ZDHHC15 3’UTR. 
Red asterisk highlights where c.*182A>C occurred. 
 
To search for miRNAs putatively interacting with mutated ZDHHC15 3’UTR (c.*182A>C) we used 
miRdb custom and FindTar3 softwares. The list of miRNAs emerged from these two softwares 
resulted not consistent between each other and therefore we decided to use a third tool, 
RNAhybrid whose predictions are based on thermodynamic and statistical modeling. FindTar3 
predictions resulted validated by RNAhybrid and we chose the three miRNAs, hsa-miR-922, hsa-
miR-191-5p and hsa-miR-4797-5p, with the seed region perfectly paired to the first five 
nucleotides of ZDHHC15 3’UTR mutated site sequence (Fig.27). 
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Fig.27- RNA hybrid output for hsa-miR-922 (miR922), hsa-miR-191-5p (miR191-5p) and hsa-miR-4797-5p 
(miR4797-5p) and the mutant 3’UTR sequence. Red arrow highlights the c.*182A>C variant. 
 
The expression pattern of the two miRNAs putatively interacting with wild type ZDHHC15 3’UTR 
and of the three miRNAs putatively interacting with mutated ZDHHC15 3’UTR was checked on 
tissue expression Atlas (https://www.ebi.ac.uk/; https://www.ncbi.nlm.nih.gov/geo/). 
Interestingly, we found that hsa-miR-142-5p is highly expressed in brain while hsa-miR-922, 
hsa-miR-191-5p and hsa-miR-4797-5p are variably expressed in frontal cortex and cerebellum.  
To validate the predicted miRNAs in vitro we tested their inhibitory effect on ZDHHC15 3’UTR 
sequence (321bp) using luciferase assay. We co-transfected HEK293T cell line with a luciferase 
reporter plasmid containing wild type or mutated ZDHHC15 3’UTR fragments (321bp) and each 
of the selected miRNAs (hsa-miR-142-5p, hsa-miR-5590-3p, hsa-miR-922, hsa-miR-191-5p and 
hsa-miR-4797-5p). 
According to in silico predictions, miR-5590-3p significantly downregulated luciferase 
transcripts containing wild type 3’UTR sequence. In particular a significant and specific 
downregulation of wild type transcript to 0.80 fold was observed compared to negative control 
miRNA (Fig.28A). Regarding miR-142-5p, it downregulated significantly both wild type and 
mutated luciferase transcripts to respectively 0.84 and 0.91 fold (Fig.28B).  
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Fig.28- Relative luciferase activity of wild type (ZDHHC15 3’UTR) and mutant (ZDHHC15 3’UTR) firefly constructs 
in HEK293T cells transfected with negative control miRNA (miRNA-), miR-142-5p or miR-5590-3p. Normalized 
firefly luciferase activity was represented relative to control miRNA transfected cells. A) hsa-miR-5590-3p bar 
graph; B) hsa-miR-142-5p bar graph. Mean ± SEM; n=8; One-Way Anova with Tukey post-hoc Test *P<0.05 ; 
***P<0.001. 
 
Regarding the set of miRNAs putatively binding the mutated 3’UTR sequence we observed that 
luciferase values were significantly decreased for mutated ZDHHC15 3’UTR reporter construct 
only with transfection of miR-4797-5p (Fig.29). Specifically, miR-4797-5p downregulated to 0.78 
fold the luciferase activity of the construct containing the mutant 3’UTR sequence (Fig.29A), 
while no significant change in luciferase activity was observed neither using miR-922 (Fig.29B) 
nor using miR-191-5p in the assay (Fig.29C).  
 
Fig.29- Relative luciferase activity of wild type (ZDHHC15 3’UTR) and mutant (ZDHHC15 3’UTR) firefly constructs 
in HEK293T cells transfected with negative control miRNA (miRNA-), miR-4797-5p, miR-922 and miR-191-5p. 
Normalized firefly luciferase activity was represented relative to control miRNA transfected cells. A) hsa-miR-
4797-5p; B) hsa-miR-922 bar graph; C) hsa-miR-191-5p bar graph. Mean ± SEM; n=3; One-Way Anova with Tukey 
post-hoc Test *P<0.05. 
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In conclusion among the miRNAs emerged from prediction softwares only hsa-miR-5590-3p and 
hsa-miR-4797-5p resulted validated in vitro by luciferase assays. miR-5590-3p specifically 
downregulated the luciferase activity of firefly construct containing wild type ZDHHC15 3’UTR 
(Fig.28A), while miR-4797-5p specifically downregulated the luciferase activity of firefly 
construct containing mutated ZDHHC15 3’UTR (Fig.29A). Thus we can speculate that c.*182A>C 
transversion found in SMS2 patient may have an effect by creating a new binding site for hsa-
miR-4797-5p and in parallel by abolishing hsa-miR-5590-3p target site.  
 
4.3.4_Analysis of ZDHHC15 protein content in whole blood 
Due to the 3’UTR role in translational control, we investigated ZDHHC15 protein levels in the 
available whole blood cellular extracts from SMS2 patient, four healthy controls and a positive 
control cell line (such as the human neuroblastoma SK-N-BE cells). We set up protein extraction 
and performed Western Blot analysis using anti-ZDHHC15 commercial antibody. We failed to 
detect any specific ZDHHC15 band although all samples were positive for GAPDH marker. The 
company later confirmed that their antibody was ineffective and other commercial antibodies 
were not available for further testing. Thus we were unable to define c.*182A>C 3’UTR 
transversion effect at protein level. 
 
4.4_Prediction of putative palmitoylation sites in RAI1 and other 
proteins related to circadian rhythms 
 
As mentioned before, ZDHHC15 encodes for a palmitoyl-transferase (PAT), a family of enzymes 
that catalyze the transfer of a palmitate on cysteine residue of its target protein, by thioester 
bond. Palmitoylation is a reversible post-translational modification that modulates protein 
trafficking and stability (Mitchell et al 2010). Actually ZDHHC15 specific substrates are not 
known, but zdhhc15b, the zebrafish horthologue of human ZDHHC15, was shown to be crucial 
for dopaminergic neuron development (Wang et al 2015). Since both zdhhc15b and RAI1 play a 
role in neurodevelopment (Bi et al 2005; Tahir et al 2014; Wang et al 2015; Huang et al 2016), 
we wondered whether RAI1 would have any palmitoylation sites further supporting a possible 
functional correlation between RAI1 and ZDHHC15 proteins. Despite the lack of a common 
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canonical consensus sequence for palmitoylation (el-Husseini Aelm, Bredt 2002; Linder, 
Deschens 2003), CSS-Palm software which allows in silico predictions of potentially 
palmitoylated peptide sites was interrogated (Zhou et al 2006). Basically the higher the score of 
a peptide sequence predicted by CSS-Palm is, the higher confidently we may assert that this 
peptide may be palmitoylated. In silico analysis by CSS palm software revealed putative 
palmitoylation sites in RAI1 aminoacidic sequence (Tab.7). 
Tab.7- RAI1 predicted sites CSS-Palm output.  
ID Position Peptide Score Cutoff Type     
RAI1 8 MQSFRERCGFHGKQQ 1.644 1.396 S-Palmitoylation: Cluster C 
  1516 QPPEGRPCQPQTRAQ 1.671 1.396 S-Palmitoylation: Cluster C 
  1687 LSTSCLVCCLCQNPA 2.907 1.396 S-Palmitoylation: Cluster C 
  1688 STSCLVCCLCQNPAN 1.426 1.396 S-Palmitoylation: Cluster C 
  1783 LSRRLQSCYCCDGRE 1.916 1.396 S-Palmitoylation: Cluster C 
  1785 RRLQSCYCCDGREDG 3.09 3.076 S-Palmitoylation: Cluster B 
  1869 EAGATIGCCHKGCLH 1.592 1.396 S-Palmitoylation: Cluster C 
In particular, RAI1 is predicted to have seven palmitoylation sites mostly located within the C-
terminal domain (Fig.30) and two of them at aminoacidic positions 1687 and 1785 having an 
high clustering score close to 3.0 (Tab.7).   
 
Fig.30- RAI1 protein with putative palmitoylation sites. Cysteine position is labeled in blue, red asterisks 
highlight cysteines with highest prediction score. 
To further corroborate the hypothesis that ZDHHC15 may play a role in the same biological 
pathways of RAI1, in silico prediction analysis by CSS-Palm software was extended to MBD5 and 
HDAC4 proteins which were previously shown to be related to RAI1 gene expression (Williams 
et al 2010 b; Mullegama et al 2015 a). Both MBD5 and HDAC4 resulted putatively 
palmitoylated, specifically HDAC4 displayed a clustering score >3 for the cysteine 932 (Tab.8). 
Due to involvement of RAI1 in circadian gene control (William et al 2012) and the clinical 
relevance of circadian rhythms alterations in Smith Magenis Syndrome, an eventual link 
between ZDHHC15 and circadian gene was postulated. Thus we extend our analysis with CSS-
Palm software to 16 main circadian proteins (BMAL1, BMAL2, CLOCK, CRY1, CRY2, CSNK1D, 
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CSNK1E, FBXL3, NR1D1, NR1D2,  PER1, PER2, PER3, RORA, RORB, RORC). According to in silico 
predictions 9 of them (BMAL1, BMAL2, CLOCK, FBXL3, PER1, PER2, PER3, RORA and RORB) are 
supposed to be palmitoylated (Tab.8). Notably, 5 out of 9 show up to three palmitoylation sites 
(BMAL1, PER2, PER3, RORA and RORB) (Tab.8).  
In line with the observation that RAI1 may control BDNF gene expression (Bi et al 2005) and 
that RAI1 and its putative interactor SIRT1 seem to regulate neuronal plasticity and circadian 
rhythms genes (Garay et al 2016), we checked whether SIRT1 and BDNF might also be 
palmitoylated. SIRT1 amminoacidic sequence resulted potentially palmitoylated in two sites, 
with a clustering score >3.5 at cysteine 371 (Tab.8) while BDNF did not have any predicted 
palmitoylation site (Tab.8).  
Tab. 8- RAI1 regulators and circadian proteins palmitoylation sites 
ID Position Peptide Score Cutoff Type     
BDNF No site predicted             
BMAL1 35 LGTSGVDCNRKRKGS 2.123 1.396 S-Palmitoylation: Cluster C 
  240 TPGPSRLCSGARRSF 3.236 3.076 S-Palmitoylation: Cluster B 
BMAL2 20 VLREENQCIAPVVSS 2.45 1.983 S-Palmitoylation: Cluster A 
CLOCK 7 *MLFTVSCSKMSSIV 1.999 1.396 S-Palmitoylation: Cluster C 
CRY1 No site predicted             
CRY2 No site predicted             
CSNK1D No site predicted             
CSNK1E No site predicted             
FBXL3 63 RAHASQVCRNWNQVF 3.899 3.076 S-Palmitoylation: Cluster B 
HDAC4 982 GHDLTAICDASEACV 3.547 3.076 S-Palmitoylation: Cluster B 
MBD5 315 PVMKKPMCNFSTNME 1.44 1.396 S-Palmitoylation: Cluster C 
NR1D1 No site predicted             
NR1D2 No site predicted             
PER1 550 PVTFQQICKDVHLVK 3.275 3.076 S-Palmitoylation: Cluster B 
PER2 962 IPRQPCACPATRATP 1.649 1.396 S-Palmitoylation: Cluster C 
  1084 LGSGSLGCDASPSGA 2.314 1.396 S-Palmitoylation: Cluster C 
PER3 204 RAAARYECAPVKPFF 3.13 3.076 S-Palmitoylation: Cluster B 
  778 AHQNAQPCCPSAASS 3.923 3.076 S-Palmitoylation: Cluster B 
  876 LSPSFLPCPFLGATA 2.648 1.396 S-Palmitoylation: Cluster C 
RORA 25 PWSIMGHCLRTGQAR 1.419 1.396 S-Palmitoylation: Cluster C 
  73 AFVLTGVCCSWRQNG 1.777 1.396 S-Palmitoylation: Cluster C 
RORB 10 AQIEVIPCKICGDKS 2.183 1.396 S-Palmitoylation: Cluster C 
  13 EVIPCKICGDKSSGI 1.799 1.396 S-Palmitoylation: Cluster C 
  454 KELFNPDCATGCK** 4.792 3.076 S-Palmitoylation: Cluster B 
RORC No site predicted             
SIRT1 67 VPAAARGCPGAAAAA 1.426 1.396 S-Palmitoylation: Cluster C 
  371 GSFATASCLICKYKV 3.586 3.076 S-Palmitoylation: Cluster B 
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4.5_Effect of ZDHHC15 and RAI1 knockdown on expression of circadian 
rhythm-related genes 
 
In order to support ZDHHC15 involvement in SMS manifestation, specifically in circadian 
rhythm, we set up gene silencing experiments in human BE (2)-M17 neuroblastoma cells to 
check whether RAI1 and ZDHHC15 knockdown would raise the same effect. Even though RAI1 
involvement in circadian rhythm-related genes has been already reported in a previous 
publication (Williams et al 2012) we wanted to repeat the silencing experiments using a 
neuronal cell line expressing both RAI1 and ZDHHC15.  
We obtained a gene silencing efficiency of 42% and 62% for RAI1 (Fig.31A) and ZDHHC15 
(Fig.31B), respectively, compared to negative control siRNA silenced cells. To reveal eventual 
expression change in genes directly related to RAI1 (MBD5, HDAC4), possibly  interacting with 
RAI1 at chromatin level (SIRT1) (Garay et al 2016), and main circadian genes (BMAL1, BMAL2, 
CLOCK, CRY1, CRY2, CSNK1D, CSNK1E, FBXL3, NR1D1, NR1D2, PER1, PER2, PER3, RORA, RORB, 
RORC), we performed RT-qPCR assay.  
We first evaluated whether knockdown of RAI1 gene would have any effect on the expression 
level of ZDHHC15 and vice versa. RAI1 silenced samples did not show any change in ZDHHC15 
gene expression levels (Fig.31C). On the contrary a marked, even if not significant, upregulation 
of RAI1 expression levels was observed in ZDHHC15 silenced samples (Fig.31D). We should 
probably increase the number of experiments to reach statistical significance.  
The gene expression level of RAI1 putative regulators HDAC4 and MBD5 showed no significant 
changes neither in RAI1 silenced (Fig. 31C) nor in ZDHHC15 silenced cells (Fig. 31D). In ZDHHC15 
knocked down cells an increase in HDAC4, MBD5 and SIRT1 mRNA content was observed even 
though without statistical significance (Fig. 31D).  
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Fig.31- Gene silencing experiments and quantitative analysis of gene expression changes.  A) RAI1 B) ZDHHC15 
were knocked down in BE(2)-M17 cells using a stealth miRNA with medium GC content as negative control 
(siCTRL) and their gene silencing efficiency was evaluated by RT-qPCR assay (Mean ± SEM; n=4; One tailed 
Student T-test ***P<0.0001). Fold change values of putatively RAI1 regulators HDAC4 and MBD5, interactor 
SIRT1 and “indirect modulator” ZDHHC15 in C) RAI1 silenced and in D) ZDHHC15 silenced cells are indicated 
(black bar) compared to negative control siRNA (white bar).  
 
Among the circadian rhythms genes tested (CLOCK, BMAL1, PER3, BMAL2, RORC, FBXL3, 
CSNK1D, CSNK1E, NR1D1, NR1D2, PER1, PER2, CRY1, CRY2) a statistically significant 
dysregulation of PER3, RORC, CSNK1D, CSNK1E, NR1D1, PER2 and CRY1 gene expression levels 
in RAI1 silenced cells emerged by RT-qPCR analysis (Fig.32). PER3, CSNK1D, CSNK1E, PER2 and 
CRY1 mRNA content resulted downregulated, whereas RORC and  NR1D1 gene expression 
levels resulted upregulated in RAI1 silenced samples compared to negative control siRNA 
(Fig.32). Notably, RORC gene expression increased by 3.25 fold compared to negative control 
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siRNA (Fig.32). A trend to increase in CRY2 gene expression was observed even if not statistical 
significant (Fig.32).  
 
Fig.32- Quantitative analysis of circadian rhythm genes expression level (fold change) in RAI silenced samples. 
Negative control siRNA (white bar) vs RAI silenced samples (black bar). Mean ± SEM; n=4; One tailed Student T-
test *P<0.05 and ***P< 0.001. 
 
When we analyzed the expression of the circadian genes in ZDHHC15 knocked down cells 6 
(BMAL1, PER3, BMAL2, RORC, FBXL3, NR1D2) out the 14 circadian genes tested analyzed 
emerged as dysregulated by RT-qPCR assay (Fig.33). In particular mRNA levels of BMAL1, RORC 
and NR1D2 resulted upregulated compared to negative control siRNA samples with RORC and 
NR1D2 showing an increase to  2 folds (Fig.33). Whereas the gene expression levels of PER3, 
BMAL2 and FBXL3 resulted downregulated and specifically BMAL2 level decreased by  0.5 fold 
(Fig.33). Even though not statistically significant a trend to be upregulated was observed for 
CSNK1D, CSNK1E, NR1D1 and CRY2 genes in ZDHHC15 silenced samples compared to negative 
control siRNA samples (Fig.33). 
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Fig.33- Quantitative analysis of circadian rhythm genes expression levels (fold change) in ZDHHC15 silenced 
samples. Negative control siRNA (white bar) vs ZDHHC15 silenced samples (black bar). Mean ± SEM; n=4; One 
tailed Student T-test *P<0.05 and ***P< 0.001. 
 
In conclusion among 14 main circadian genes tested PER3 and RORC showed similar gene 
expression change in both RAI1 and ZDHHC15 silenced cells, specifically PER3 resulted 
downregulated while RORC markedly upregulated. 
Notably, even if not statistically significant in ZDHHC15 silenced samples, NR1D1 and CRY2 
showed a similar upregulation of their expression levels in both RAI1 and ZDHHC15 knocked 
down cells. On the other hand, RAI1 silenced cells revealed a trend opposite to ZDHHC15 
silenced ones regarding CSNK1D and CSNK1E gene expression levels, which were significant 
only in RAI1 knocked down cells. It would be worthwhile to increase the number of 
experiments to try to improve statistical  significance of these data. We failed to analyze BDNF 
gene expression levels because its expression in BE(2)-M17 in vitro system was too low (Ct>32).  
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DISCUSSION 
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Smith Magenis Syndrome (SMS, OMIM#182290) is a dominant disorder, with an estimated 
prevalence of 1:15000-25000, mainly resulting from haploinsufficiency of RAI1 gene due to 
either 17p11.2 deletion or RAI1 mutation. 
Despite RAI1 is recognized as the disease-causing gene just 50% of patients with a suspicion of 
SMS have SMS classical genetic defects, thus it is likely that other loci, with a role in the same 
RAI1 functional pathway or regulating directly RAI1 transcription, might be involved in SMS 
aetiology and eventually explain SMS similar phenotypes. Indeed recent array CGH studies on 
SMS-like cohort identified patients with two SMS overlapping syndromes, 2q23.1 deletion 
syndrome (OMIM#156200) and Brachydactly Mental Retardation syndrome (BDMR, 
OMIM#600430), due to MBD5 and HDAC4 haploinsufficiency respectively (Williams et al 2010 
a). MBD5 and HDAC4 are two chromatin remodelers crucial for brain plasticity (Talkowski et al 
2011; Sando et al 2012); interestingly patients with MBD5 or HDAC4 haploinsufficiency display 
RAI1 downregulation, according to their SMS overlapping phenotypes (Williams et al 2010 b; 
Mullegama et al 2015 a). Genome-wide approach on a cohort of patients with a clear SMS 
phenotype but lacking 17p11.2 microdeletion or RAI1 molecular defects is useful to unravel 
RAI1 functional pathways. Indeed, even if RAI1 is recognized as the disease-causing gene its 
detailed role in different molecular pathways remains elusive. Several animal models support 
RAI1 crucial contribution to brain development and plasticity, by interacting at chromatin 
promoter and enhancer regions, but compelling evidences on RAI1 regulators, interactors and 
targets are still missing. 
Therefore a previously selected cohort of 40 patients analyzed according to diagnostic 
guidelines and negative to 17p11.2 microdeletion or RAI1 mutations, thus referred as “Smith 
Magenis like patients” (SMS-like), was screened with high resolution array CGH analysis 
searching for rare CNVs with a putative pathogenic effect because disrupting dosage-sensitive 
genes implicated in the onset of SMS phenotype. The present analysis revealed to be effective 
in identifying candidate genes possibly implicated in RAI1 functional pathway. Indeed, among 
SMS-like patients a rare 54 kb deletion on Xq13.3 identified in a male patient (SMS1) and 
maternally inherited was considered to be of particular interest because, even if the deletion 
does not involve any genes, maps 29 kb far from the 5’UTR of ZDHHC15 (Zinc Finger DHHC 
domain-containing protein 15), a gene previously found not expressed in a patient with a 
nonsyndromic X-linked intellectual disability (XLID) (Mansouri et al 2005). Notably, in SMS1, 
ZDHHC15 transcript resulted statistically downregulated according to RT-qPCR analyses: in our 
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hypothesis, the Xq13.3 deletion, removing a conserved insulator element with CTCF binding 
site, might have perturbed the chromatin status by a position effect, thus leading to 
heterochromatinization of the adjacent region and a subsequent gene downregulation (Fig.34).  
 
 Fig.34- Model of position effect hypothesis. Variation of chromatin conformation due to the insulator loss. 
Genomic deletion including insulator (blue blocks) might switch an euchromatic gene region (upper side of 
panel) to heterochromatic state (bottom side of panel) alteration causing silencing/downregulation of the 
flanking gene/nearby gene. Promoter and enhancer are shown respectively as red and yellow blocks, 
heterochromatic status by grey pattern thick line. 
As we posited a long range heterochromatinization it might be helpful to investigate the 
expression levels of ZDHHC15 neighboring genes and eventually look at methylation status of 
their promoters to further sustain our hypothesis.  
This hypothesis is also confirmed by an in silico analysis searching for Topologically Associated 
Domains (TADs) in Xq13.3 deleted region. Recent studies on chromatin three-dimensional 
nuclear organization of mammalian genomes revealed the presence of genomic regions called 
TADs (Lupianez et al 2015) that if disrupted (e.g. due to genomic structural variants) could 
affect the expression of nearby genes often leading to diseases (Lupianez et al 2016). As shown 
in Fig.35 the Xq13.3 deletion identified in SMS1 seems to disrupt the boundaries of two/three 
adjacent TADs. Assuming that the TAD in which ZDHHC15 localizes is actively transcribed and 
that the distal one is inactively transcribed, the lack of these boundaries might have altered the 
chromatin status of the active TAD, thus supporting our RT-qPCR data and the assumption of a 
long range heterochromatinization. 
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Fig.35- Hi-C data visualization on UCSC genome browser. GM12878 cell line with 1 kb resolution was selected. 
TADs are visualized by dotted lines. SMS1 deletion with the insulator element predicted (in light blue) is shown 
upstream 5’UTR of ZDHHC15 (http://promoter.bx.psu.edu/hi-c/view.php). 
 
As previously mentioned Mansouri et al. described in 2005 a female patient with a severe 
intellectual disability who carries a balanced reciprocal t(X;15)(q13.3;cen). The breakpoint at 
Xq13.3 is located within the first exon of ZDHHC15 gene resulting in absence of any ZDHHC15 
transcripts due to an expected shewed X inactivation. Interestingly, although this patient and 
SMS1 share some clinical features (i.e. intellectual disability, hypotonia, speech delay and 
aggressive behavior), the phenotype of the female patient reported by Mansouri et al. is more 
ZDHHC15 
Insulator 
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severe compared to SMS1 phenotype; this can be explained by her complete lack of ZDHHC15 
expression compared to the downregulation observed in SMS1.  
Supporting the relationship between ZDHHC15 and SMS-like manifestations, the subsequent 
Sanger sequencing performed on all male patients within SMS-like cohort, identified a second 
male patient (SMS2) with a rare variant (c.*182A>C) in 3’UTR regulatory region of ZDHHC15 
that was maternally inherited. Further quantitation of gene transcript levels in SMS2 revealed 
the possibility that a slight downregulation occurred. Even though Real Time data were not 
significant in the tissue analyzed it cannot be ruled out that a gene downregulation might be 
more evident in other tissues mainly involved in SMS pathophysiology.  
Supporting the idea that the variant identified in SMS2 patient might raise an effect on 
ZDHHC15 regulation, in vitro experiments using selected miRNAs for wild type and mutated 
sequence, revealed that SMS2 variant might effectively abolish a miRNA physiological binding 
site (hsa-miR-5590-3p downregulated only wild type 3’UTR of ZDHHC15) and create a new one 
(hsa-miR-4797-5p downregulated only mutated 3’UTR of ZDHHC15). Notably, hsa-miR-4797-5p 
expression is supposed to be variable in cerebellum and frontal cortex thus eventually 
explaining why on blood derived RNA ZDHHC15 levels of SMS2 resulted just slightly 
downregulated. 
Our focus on ZDHHC15 as good candidate for SMS-like manifestation raised also according to its 
biological function. ZDHHC15 encodes for palmitoyl-transferase 15 ubiquitously expressed, but 
highly expressed in brain. Palmitoyl-transferases (PATs) are a family of enzymes that catalyze 
the transfer of a palmitate on Cys residue of its target protein by thioester bond.  The PAT gene 
family is deeply conserved across eukaryotes. Seven PAT genes are observed in yeast while 
tewnty-two in humans (Ohno et al 2006), encoding for their respective proteins, thus 
suggesting a fine tuned substrate specificity. In the past decade many advances were done to 
understand the palmitoylation and its relevance in brain (Fukata, Fukata 2010). 
Aberrant/defective palmitoylation has already been linked to Neuronal Lipofucinosis, Alzheimer 
Disease, mental retardation, Huntington Disease (Young et al 2012), thus giving compelling 
evidences of the critical role of PATs in neurodevelopmental and neuron survival processes. 
Recent palmitoylome studies on different cell types determined the palmitoylation contribution 
to several processes including cancer, immunity and synaptic function (Sanders et al 2015). This 
enrichment analyses revealed a potential role for palmitoylation at synapses since the 41% of 
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synaptic genes was found palmitoylated (Sanders et al 2015). About ZDHHC15 specific function 
is only reported a study in which zebrafish Zdhhc15b, ZDHHC15 human orthologue, was found 
to be crucial in diencephalic dopaminergic neurons differentiation (Wang et al 2015). Actually 
ZDHHC15 specific substrates are not known. 
Based on ZDHHC15 role in post-translational modification and sustaining the idea that 
ZDHHC15 might modulate directly RAI1, thus being implicated in SMS/SMS-like onset, in silico 
analysis of RAI1 protein revealed two cysteine residues likely to be palmitoylated at C-terminal 
domain. Since this domain is crucial for RAI1 nuclear localization (Carmona Mora et al 2012), we 
can speculate that a defective palmitoylation might lead to RAI1 mislocalization, thus affecting 
RAI1 physiological/intracellular function and/or mimicking RAI1 haploinsufficiency. If this idea is 
validated in vitro, it might explain why either RAI1 either ZDHHC15 downregulation results in 
similar neurological/neurobehavioural phenotypes. This eventual direct connection needs to be 
further addressed with other experimental procedures. 
The hypothesis of an eventual indirect connection between ZDHHC15 and RAI1 was further 
supported by extending in silico palmitoylation predictions to RAI1 putative regulators (HDAC4 
and MBD5) and interactor SIRT1, that showed for each protein an high score for palmitoylation. 
Due to the relevance of sleep disturbance phenotype in SMS, also some of the circadian genes 
(n=9) are predicted to be palmitoylated, supporting ZDHHC15 indirect connection with RAI1 
and circadian rhythms.   
These results corroborated the hypothesis of ZDHHC15 as a good candidate for SMS-like 
manifestation and prompt us to further elucidate its molecular pathways in connection with 
RAI1 and circadian rhythms throughout in vitro silencing experiments on BE(2)-M17 human 
neuroblastoma cells. Remarkably RT-qPCR data revealed a marked upregulation of RAI1 
transcripts in ZDHHC15 silenced samples, while no differences in ZDHHC15 expression was 
observed in RAI1 silenced samples. This result, even if not significant, revealed that ZDHHC15 
could have an effect on RAI1 transcript regulation by an indirect connection due to its role in  
post-translational regulation. Indeed, in this hypothesis ZDHHC15 might palmitoylate RAI1 
transcriptional regulators, thus leading to its overexpression. 
According to RAI1 overexpression identified in ZDHHC15 knocked-down cells, it seems that this 
gene might be not related to SMS where RAI1 haploinsufficiency is found. Intriguingly RAI1 
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overexpression is the molecular cause of Potocki-Lupski (PTLS, OMIM#610883), a syndrome 
that shares with SMS several traits but an overall milder phenotype and represents one of SMS 
differential diagnosis chance. Indeed both SMS1 and SMS2 patients present most of the clinical 
signs shared between SMS and PTLS (i.e. short stature, brachydactyly, cardiovascular 
abnormalities, hypotonia, speech delay, Developmental Delay, Intellectual Disability, sleep 
disturbance, seizures, hyperactivity, ASD).  
Moreover RT-qPCR analyses showed an overall upregulation, even if not significant, of RAI1 
putative positive regulators HDAC4 and MBD5 in ZDHHC15 silenced samples. These data 
allowed us to further postulate that ZDHHC15 might exert an indirect control on RAI1 
transcription. On the other hand, as previously reported (Williams et al 2010 b; Mullegama et al 
2015 a), no change in HDAC4 and MBD5 expression was observed in RAI1 silenced samples. 
Thus HDAC4, MBD5 upregulation and RAI1 overexpression in ZDHHC15 silenced samples are 
consistent with a role for ZDHHC15 in RAI1 modulation and in line with previously reported 
data (Williams et al 2010 b; Mullegama et al 2015 a). 
Among 14 circadian regulators transcripts levels tested in BE(2)-M17 RAI1 silenced samples, 7 
resulted significantly dysregulated, 5 unaffected and 2 showed a dysregulation trend. In 
particular, PER3 and CRY1 significant downregulation showed on BE(2)-M17 is consistent with 
the data observed in HEK293T RAI1 silenced samples (Williams et al 2012). On the contrary 
CLOCK, BMAL1 and NR1D2 levels observed in BE(2)-M17 RAI1 silenced samples are unaffected 
and NR1D1 and RORC are upregulated showing an opposite trend compared to HEK293T 
(Williams et al 2012). Upregulation as well as no differences observed for some of the circadian 
genes might reflect a cell specificity trend. It is likely that a neuroblastoma, as CNS tissue 
derived cell line, may have a different homeostasis of main circadian genes. 
Regarding ZDHHC15 silenced BE(2)-M17 samples, 6 out of 14 circadian regulators transcripts 
levels resulted significantly deregulated, 4 did not change and 4 displayed a deregulated trend. 
Among significantly downregulated genes tested, PER3 resulted consistent with a recent report 
on Potocki Lupski patient synchronized lymphoblasts (Mullegama et al 2017).  
Strikingly both RAI1 and ZDHHC15 silenced cells displayed significant deregulation of expression 
in up to half of the circadian genes tested thus sustaining an interconnection among ZDHHC15, 
RAI1 and circadian rhythms. Specifically, CLOCK and PER1 expression levels did not change, 
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PER3 resulted downregulated while RORC markedly upregulated, in both RAI1 and ZDHHC15 
knockdown cells. Further analysis are needed to clarify how ZDHHC15, RAI1 and circadian 
rhythms are connected each other (mechanistic insight). 
In conclusion the data discussed further corroborate the hypothesis of ZDHHC15 as novel 
candidate gene possibly explaining SMS-like condition. Useful approaches to clarify the detailed 
connection between RAI1 and ZDHHC15 might be transcriptomic and/or proteomic studies on  
in vitro model BE(2)-M17 and patients derived iPS cells.   
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